S-4/A 1 fs42021a3_cmlifesci2.htm REGISTRATION STATEMENT

As filed with the United States Securities and Exchange Commission on August 5, 2021.

Registration No: 333-256127

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________________

Amendment No. 3
to
FORM S
-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

_____________________________

CM LIFE SCIENCES II INC.

(Exact name of registrant as specified in its charter)

_____________________________

Delaware

 

001-40090

 

85-4298912

(State or other jurisdiction of
incorporation or organization)

 

(Primary Standard Industrial
Classification Code Number)

 

(I.R.S. Employer
Identification Number)

c/o Corvex Management LP
667 Madison Avenue
New York, New York 10065
Telephone: (212) 474
-6745

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

_____________________________

Eli Casdin
c/o Corvex Management LP
667 Madison Avenue
New York, New York 10065
Telephone: (212) 474
-6745
(Name, address, including zip code, and telephone number, including area code, of agent for service)

_____________________________

Copies to:

Joel Rubinstein
Matthew Kautz
Andrew J. Ericksen
White & Case LLP
1221 Avenue of the Americas
New York, NY 10020
-1095
(212) 819
-8200

 

Herbert F. Kozlov
Ari Edelman
Jared Kelly
Lynwood E. Reinhardt
Reed Smith LLP
599 Lexington Avenue
New York, NY 10022
-7650
(212) 521
-5400

_____________________________

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective and all other conditions to the transactions contemplated by the Merger Agreement described in the included proxy statement/prospectus have been satisfied or waived.

If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

     

Accelerated filer

 

Non-accelerated filer

 

     

Smaller reporting company

 

           

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:

Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

Exchange Act Rule 14-1(d) (Cross-Border Third-Party Tender Offer)

 

Table of Contents

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered

 

Amount to be Registered

 

Proposed
Maximum
Offering
Price
Per Share

 

Proposed
Maximum
Aggregate
Offering
Price

 

Amount of
Registration
Fee

Class A common stock, par value $0.0001 per share

 

130,000,000

(1)

 

$

11.69

(2)

 

$

1,519,700,000

(2)

 

$

165,799.27

(3)(4)

Total

   

 

 

 

 

 

 

 

 

 

 

 

 

 

____________

(1)      Based on the maximum number of shares of Class A common stock, par value $0.0001 per share (“CMLS II Class A common stock”), of the registrant estimated to be issued in connection with the business combination described herein (“Business Combination”). Such maximum number of shares of CMLS II Class A common stock is based on (a) up to 125,000,000 shares of CMLS II Class A common stock to be issued to the holders of shares of SomaLogic, Inc. (“SomaLogic”), plus (b) up to 5,000,000 shares of CMLS II Class A common stock to be issued as Earn-Out Shares (as defined below). The exchange ratio is currently expected to be 0.8426 shares of CMLS II Class A common stock per share of SomaLogic Class B common stock, after giving effect to the conversion of each share of SomaLogic preferred stock into two shares of SomaLogic Class B common stock.

(2)      Pursuant to Rules 457(c) and 457(f)(1) promulgated under the Securities Act of 1933, as amended (“Securities Act”), and solely for the purpose of calculating the registration fee, the proposed maximum aggregate offering price is calculated as the product of (i) 130,000,000 shares of CMLS II Class A common stock and (ii) $11.69, the average of the high and low trading prices of CMLS II Class A common stock on May 10, 2021 (within five business days prior to the date of this Registration Statement).

(3)      Calculated pursuant to Rule 457 under the Securities Act by multiplying the proposed maximum aggregate offering price of securities to be registered by 0.0001091.

(4)      Previously paid.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

Table of Contents

The information in this preliminary proxy statement/prospectus is not complete and may be changed. These securities may not be issued until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus statement/prospectus is not an offer to sell these securities and does not constitute the solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY — SUBJECT TO COMPLETION DATED AUGUST 5, 2021

PROXY STATEMENT/PROSPECTUS
DATED            , 2021

CM LIFE SCIENCES II INC.

c/o Corvex Management
667 Madison Avenue
New York, New York

Dear Stockholder of CM Life Sciences II Inc.:

You are cordially invited to attend the special meeting of stockholders (“Special Meeting”) of CM Life Sciences II Inc. (“we,” “us,” “our”, “CMLS II” or the “Company”) to be held on [day], [date] at [time] Eastern time at [virtual meeting link]. In light of ongoing developments related to coronavirus (COVID-19), after careful consideration, the Company has determined that the Special Meeting will be a virtual meeting conducted exclusively via live webcast in order to facilitate stockholder attendance and participation while safeguarding the health and safety of our stockholders, directors and management team. You or your proxyholder will be able to attend and vote at the Special Meeting online by visiting [virtual meeting link] and using a control number assigned by Continental Stock Transfer & Trust Company. To register and receive access to the virtual meeting, registered stockholders and beneficial stockholders (those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in the proxy statement/prospectus.

On March 28, 2021, the Company and its wholly owned subsidiary, S-Craft Merger Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger, as amended by Amendment No. 1 and Amendment No. 2 thereto (the “amendments”), dated as of May 12, 2021 and July 15, 2021, respectively (as so amended and may be further amended from time to time, the “Merger Agreement”) with SomaLogic, Inc. (“SomaLogic”), a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached as Annex A to this proxy statement/prospectus. If the Merger Agreement is approved by the Company’s stockholders at the Special Meeting (and all other conditions pursuant to the Merger Agreement are either satisfied or waived), Merger Sub will merge with and into SomaLogic, with SomaLogic surviving the merger as a wholly owned subsidiary of the Company (“Merger”). Upon the consummation of the transactions contemplated by the Merger Agreement (“Business Combination”), the Company will change its name to SomaLogic, Inc. As described in this proxy statement/prospectus, CMLS II’s stockholders are being asked to consider and vote upon, among other things, the Business Combination and the other proposals set forth herein. For ease of reference, certain capitalized terms used in this proxy statement/prospectus are defined below in “Frequently Used Terms.

Under the Merger Agreement, CMLS II has agreed to acquire all of the outstanding equity interests of SomaLogic for at least $1.25 billion in aggregate consideration consisting of 125,000,000 shares of CMLS II Class A common stock (assuming no cash elections will be made by SomaLogic stockholders) and up to an additional 5,000,000 shares of CMLS II Class A common stock pursuant to the Earn-Out Shares (as defined below). Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (“Effective Time”), and as further described in this proxy statement/prospectus, (i) each share of SomaLogic common stock and SomaLogic preferred stock held in SomaLogic’s treasury or owned by the Company, Merger Sub or SomaLogic immediately prior to the Effective Time (each an “Excluded Share”), will be cancelled and no consideration will be paid or payable with respect thereto and (ii) each share of SomaLogic stock, other than Excluded Shares and Dissenting Shares (as defined in the Merger Agreement), that is issued and outstanding immediately prior to the Effective Time will be cancelled and automatically deemed for all purposes to represent the right to receive a portion of the total consideration, with each SomaLogic’s stockholder (as applicable) being entitled to receive (the consideration in clauses (a) through (c), the “Merger Consideration”):

(a)     if such stockholder has made a cash election as set forth and in accordance with the terms of the Merger Agreement, a portion of the specified aggregate amount of cash consideration payable under the terms of the Merger Agreement (such aggregate amount not to exceed $50,000,000) and pursuant to the terms of such stockholder’s cash election;

(b)    a number of shares of Class A common stock, par value $0.0001 per share, of CMLS II (“CMLS II Class A common stock”) equal to the quotient of: (i) (A) the product of (x) such stockholder’s total shares of SomaLogic stock (with the SomaLogic common stock and preferred stock (determined on

 

Table of Contents

an as-converted basis) included as a single class) multiplied by (y) the per share amount calculated in accordance with the Merger Agreement minus (B) the amount of cash payable to such stockholder pursuant to its cash election, described in clause (a) above, if any, divided by (ii) $10.00; and

(c)     such stockholder’s earn-out pro rata share of any Earn-Out Shares (as defined below) to which such stockholder is entitled pursuant to the terms of the Merger Agreement.

The exchange ratio is currently expected to be 0.8426 shares of CMLS II Class A common stock per share of SomaLogic’s Class B common stock, after giving effect to the conversion of each share of SomaLogic preferred stock into two shares of SomaLogic Class B common stock.

Following the closing of the Business Combination, and as additional consideration for the Merger and the other transactions, if at any time between the 13-month anniversary of the closing and the 24-month anniversary of the closing (inclusive of the first and last day of such period, the “Earn-Out Period”), the volume-weighted average closing sale price of a share of CMLS II Class A common stock as reported on Nasdaq for a period of at least 20 out of 30 consecutive trading days ending on the trading day immediately prior to the date of determination is greater than or equal to $20.00 (“Triggering Event”), then we will deliver or cause to be delivered to each applicable SomaLogic stockholder in accordance with such stockholder’s respective earn-out pro rata share (other than holders of Dissenting Shares, as defined in the Merger Agreement), and each employee or individual service provider of SomaLogic, in each case whom the board of directors of SomaLogic designates as an Earn-Out Service Provider prior to the Closing and who enters into an earn-out award agreement (such employee or individual service provider, an “Earn-Out Service Provider”) (in accordance with its respective earn-out pro rata share and, in the case of the Earn-Out Service Providers, in accordance with the terms of the applicable earn-out award agreement), 5,000,000 shares of CMLS II Class A common stock (which shall be equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares or other like change or transaction with respect to the CMLS II Class A common stock occurring on or after the Closing) (“Earn-Out Shares”), upon the terms and subject to the conditions set forth in the Merger Agreement and the other transaction agreements and, in the case of the Earn-Out Service Providers, subject to the additional requirements set forth in the Merger Agreement and the applicable earn-out award agreement.

The Business Combination will have no effect on the CMLS II Class A common stock that is issued and outstanding as of immediately prior to the Effective Time, which will continue to remain outstanding. The CMLS II Class B common stock which is held by the Company’s Initial Stockholders and referred to as the Founder Shares will automatically convert into CMLS II Class A common stock concurrently with or immediately following the consummation of the Business Combination on a one-for-one basis.

Upon the Closing, the former SomaLogic stockholders are expected to hold, in the aggregate, approximately 61.7% of the outstanding shares of the post-combination company (assuming no cash elections will be made by SomaLogic stockholders). Refer to the pro forma post-combination company common stock issued and outstanding immediately after the Business Combination and PIPE Investment in the section entitled “Unaudited Pro Forma Condensed Combined Financial Information.” Any cash paid to SomaLogic stockholders as Merger Consideration under the terms of the Merger Agreement will reduce the amount of cash that will remain on the pro forma condensed combined balance sheet of the post-combination company and be available for the payment of transaction expenses and other post-combination company uses.

In connection with the Business Combination, the Company entered into subscription agreements, each dated as of March 28, 2021 (“Subscription Agreements”), with certain institutional investors (collectively, “PIPE Investors”), including certain stockholders of SomaLogic and certain affiliates of CMLS Holdings II LLC (“Sponsor”), pursuant to which, among other things, the Company agreed to issue and sell to the PIPE Investors, in private placements to close immediately prior to the Closing, an aggregate of 37,500,000 shares of CMLS II Class A common stock at $10.00 per share, for an aggregate purchase price of $375,000,000 (“PIPE Investment”).

The Company and SomaLogic cannot complete the Business Combination unless the Company’s stockholders approve the Business Combination, including the issuance of common stock to SomaLogic stockholders as Merger Consideration, and certain of the other proposals contained herein. The Company is sending you this proxy statement/prospectus to ask you to vote in favor of the Business Combination Proposal, as described below, and the other matters described in this proxy statement/prospectus.

At the Special Meeting, the Company’s stockholders will be asked to consider and vote upon a proposal (“Business Combination Proposal” or “Proposal No. 1”) to adopt the Merger Agreement, a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached to the accompanying proxy statement/prospectus as Annex A, and approve the transactions contemplated thereby, including the Business Combination. In addition, you are being asked to consider and vote upon a proposal to approve, for purposes of complying with applicable Nasdaq Stock Market (“Nasdaq”)

 

Table of Contents

listing rules, the issuance of more than 20% of the Company’s outstanding common stock in connection with the Business Combination and the Subscription Agreements, including up to 125,000,000 shares of common stock to the SomaLogic stockholders, up to 5,000,000 Earn-Out Shares and 37,500,000 shares of common stock to the PIPE Investors (“Nasdaq Stock Issuance Proposal” or “Proposal No. 2”); a proposal to approve the SomaLogic, Inc. 2021 Omnibus Incentive Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex C (“Incentive Plan”) (“Incentive Plan Proposal” or “Proposal No. 3”); a proposal to approve the SomaLogic, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex D (“ESPP”) (“ESPP Proposal” or “Proposal No. 4”); a proposal to adopt the A&R Certificate of Incorporation in the form attached to the accompanying proxy statement/prospectus as Annex E (“Charter Amendment Proposal” or “Proposal No. 5”); a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal (“Adjournment Proposal” or “Proposal No. 6”).

Each of these proposals is more fully described in this proxy statement/prospectus, which each stockholder is encouraged to carefully read.

Pursuant to our current Certificate of Incorporation (“Current Charter”), we are providing our public stockholders with the opportunity to redeem, upon the Closing, shares of common stock for cash equal to the pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the trust account (“Trust Account”) that holds the proceeds of our IPO (including interest not previously released to the Company to pay franchise and income taxes), subject to certain limitations. For illustrative purposes, based on the balance of the Trust Account of approximately $276 million as of March 31, 2021, the estimated per share redemption price would have been approximately $10.00. Public stockholders may elect to redeem their shares even if they vote for the Business Combination. Any request to redeem public shares, once made, may be withdrawn at any time until the deadline for exercising redemption requests and thereafter, with our consent, until the Closing. If we receive valid redemption requests from holders of public shares prior to the redemption deadline, we may, at our sole discretion, following the redemption deadline and until the date of Closing, seek and permit withdrawals by one or more of such holders of their redemption requests. We may select which holders to seek such withdrawals of redemption requests from based on any factors we may deem relevant, and the purpose of seeking such withdrawals may be to increase the funds held in the Trust Account, including where we otherwise would not satisfy the closing condition that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses.

Each redemption of shares of common stock by our public stockholders will reduce the amount in the Trust Account. The Merger Agreement provides that SomaLogic’s obligation to consummate the Business Combination is subject to the condition that that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses. This condition to closing in the Merger Agreement is for the sole benefit of, and may be waived by, SomaLogic. If, as a result of redemptions of common stock by our public stockholders, this condition is not met (or waived by SomaLogic), then SomaLogic may elect not to consummate the Business Combination. In addition, in no event will we redeem shares of our common stock in an amount that would result in the Company’s failure to have net tangible assets equaling or exceeding $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). Holders of our outstanding public warrants do not have redemption rights in connection with the Business Combination. Unless otherwise specified, the information in the accompanying proxy statement/prospectus assumes that none of our public stockholders exercise their redemption rights with respect to their shares of common stock.

Our Sponsor and the Company’s officers and directors at the time of our IPO (together, our “Initial Stockholders”) have agreed to vote their shares of common stock in favor of the Business Combination. Currently, our Initial Stockholders own approximately 20% of our issued and outstanding shares of common stock. In addition, our Initial Stockholders have agreed to waive their redemption rights with respect to such shares.

We are providing the accompanying proxy statement/prospectus and accompanying proxy card to our stockholders in connection with the solicitation of proxies to be voted at the Special Meeting (including following any adjournments or postponements of the Special Meeting). Information about the Special Meeting, the Business Combination and other related business to be considered by the Company’s stockholders at the Special Meeting is included in this proxy statement/prospectus. Whether or not you plan to attend the Special Meeting, we urge all Company stockholders to read this proxy statement/prospectus, including the Annexes and the accompanying financial statements of the Company and SomaLogic, carefully and in their entirety. In particular, we urge you to carefully read the section entitled “Risk Factors” beginning on page 47 of this proxy statement/prospectus.

 

Table of Contents

After careful consideration, our Board has approved the Merger Agreement and the transactions contemplated therein, and recommends that our stockholders vote “FOR” adoption of the Merger Agreement and approval of the transactions contemplated thereby, including the Business Combination, and “FOR” all other proposals presented to our stockholders in the accompanying proxy statement/prospectus. When you consider the Board’s recommendation of these proposals, you should keep in mind that our directors and officers have interests in the Business Combination that may conflict with your interests as a stockholder. Please see the section entitled “Proposal No. 1 — The Business Combination — Proposal – Interests of Certain Persons in the Business Combination” for additional information.

Approval of each of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal requires the affirmative vote of a majority of the votes cast at the Special Meeting. Approval of the Charter Amendment Proposal requires the affirmative vote of holders of at least a majority of the outstanding shares of our common stock.

Your vote is very important. Whether or not you plan to attend the Special Meeting, please vote as soon as possible by following the instructions in this proxy statement/prospectus to make sure that your shares are represented at the Special Meeting. If you hold your shares in “street name” through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the Special Meeting. Even if you have voted by proxy, you may still vote during the Special Meeting by visiting [virtual meeting link] with your 12-digit control number assigned by Continental Stock Transfer & Trust Company included on your proxy card or obtained from them via email. The transactions contemplated by the Merger Agreement will be consummated only if the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and the ESPP Proposal are approved at the Special Meeting. The proposals in this proxy statement/prospectus (other than the Adjournment Proposal) are conditioned on the approval of the Business Combination Proposal.

If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted “FOR” each of the proposals presented at the Special Meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the Special Meeting, the effect will be that your shares will not be counted for purposes of determining whether a quorum is present at the Special Meeting. If you are a stockholder of record and you attend the Special Meeting and wish to vote at the Special Meeting, you may revoke your proxy and vote at the Special Meeting.

TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND THAT THE COMPANY REDEEM YOUR SHARES FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO THE COMPANY’S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE SPECIAL MEETING. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING DEPOSITORY TRUST COMPANY’S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL NOT BE REDEEMED FOR CASH. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS.

On behalf of our Board, I would like to thank you for your support of CM Life Sciences II Inc. and look forward to a successful completion of the Business Combination.

 

By Order of the Board of Directors,

          , 2021

   
   

/s/ Eli Casdin

   

Eli Casdin

   

Chief Executive Officer

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PROXY STATEMENT/PROSPECTUS, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

This proxy statement/prospectus is dated             , 2021 and is expected to be first mailed to the Company’s stockholders on or about             , 2021.

 

Table of Contents

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS OF

CM LIFE SCIENCES II INC.

TO BE HELD ON              , 2021

To the Stockholders of CM Life Sciences II Inc.:

NOTICE IS HEREBY GIVEN that a Special Meeting of the stockholders of CM Life Sciences II Inc., a Delaware corporation (“Company”), will be held on [day], [date] at [time] Eastern time at [virtual meeting link] (“Special Meeting”). In light of ongoing developments related to coronavirus (COVID-19), after careful consideration, the Company has determined that the Special Meeting will be a virtual meeting conducted exclusively via live webcast in order to facilitate stockholder attendance and participation while safeguarding the health and safety of our stockholders, directors and management team. You or your proxyholder will be able to attend and vote at the Special Meeting online by visiting [virtual meeting link] and using a control number assigned by Continental Stock Transfer & Trust Company. To register and receive access to the virtual meeting, registered stockholders and beneficial stockholders (those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in the proxy statement/prospectus.

At the Special Meeting, you will be asked to consider and vote on proposals to:

1.      Proposal No. 1 — The Business Combination Proposal — To approve and adopt the Agreement and Plan of Merger, dated as of March 28, 2021, as amended by Amendment No. 1 and Amendment No. 2 thereto (the “amendments”), dated as of May 12, 2021 and July 15, 2021 (as so amended and as may be further amended and/or restated from time to time, the “Merger Agreement”) by and among the Company, its wholly owned subsidiary, Merger Sub, and SomaLogic, Inc. (SomaLogic”), a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached to this proxy statement/prospectus as Annex A, and approve the transactions contemplated thereby (“Business Combination”), including the merger of Merger Sub with and into SomaLogic, with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company, and the issuance of common stock to SomaLogic stockholders as Merger Consideration;

2.      Proposal No. 2 — The Nasdaq Stock Issuance Proposal — To approve, for purposes of complying with applicable listing rules of Nasdaq, the issuance of more than 20% of the Company’s outstanding common stock in connection with the Business Combination and Subscription Agreements, including up to 37,500,000 shares of our common stock to the PIPE Investors, which includes affiliates of our Sponsor that subscribed for 5,450,000 shares of common stock, and up to 125,000,000 shares of our common stock to SomaLogic stockholders and up to 5,000,000 Earn-Out Shares;

3.      Proposal No. 3 — The Incentive Plan Proposal — To approve the SomaLogic, Inc. 2021 Omnibus Incentive Plan, a copy of which is attached to this proxy statement/prospectus as Annex C (“Incentive Plan”), including the authorization of the initial share reserve under the Incentive Plan;

4.      Proposal No. 4 — The ESPP Proposal — To approve the SomaLogic, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to this proxy statement/prospectus as Annex D (“ESPP”), including the authorization of the initial share reserve under the ESPP;

5.      Proposal No. 5 — The Charter Amendment Proposal — To adopt the A&R Certificate of Incorporation in the form attached to the accompanying proxy statement/prospectus as Annex E; and

6.      Proposal No. 6 — The Adjournment Proposal — To approve, if necessary, the adjournment of the Special Meeting to a later date or dates to permit further solicitation and votes of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal the Incentive Plan Proposal or the ESPP Proposal. This proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal.

 

Table of Contents

The above matters are more fully described in this proxy statement/prospectus, which also includes, as Annex A, a composite copy of the Merger Agreement, incorporating the amendments into the text of the initial agreement. We urge you to carefully read this proxy statement/prospectus in its entirety, including the Annexes and accompanying financial statements of the Company and SomaLogic.

The record date for the Special Meeting is [day], [date]. Only stockholders of record at the close of business on that date may vote at the Special Meeting or any adjournment thereof. A complete list of our stockholders of record entitled to vote at the Special Meeting will be available for ten days before the Special Meeting at our principal executive offices for inspection by stockholders during ordinary business hours for any purpose germane to the Special Meeting and electronically during the Special Meeting at [virtual meeting link].

Pursuant to our Current Charter, we are providing our public stockholders with the opportunity to redeem, upon the Closing, shares of common stock for cash equal to the pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account that holds the proceeds of our IPO (including interest not previously released to the Company to pay franchise and income taxes), subject to certain limitations. For illustrative purposes, based on the balance of the Trust Account of approximately $276 million as of March 31, 2021, the estimated per share redemption price would have been approximately $10.00. Public stockholders may elect to redeem their shares even if they vote for the Business Combination. Any request to redeem public shares, once made, may be withdrawn at any time until the deadline for exercising redemption requests and thereafter, with our consent, until the Closing. If we receive valid redemption requests from holders of public shares prior to the redemption deadline, we may, at our sole discretion, following the redemption deadline and until the date of Closing, seek and permit withdrawals by one or more of such holders of their redemption requests. We may select which holders to seek such withdrawals of redemption requests from based on any factors we may deem relevant, and the purpose of seeking such withdrawals may be to increase the funds held in the Trust Account, including where we otherwise would not satisfy the closing condition that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses.

Our Initial Stockholders (as defined above), who own approximately 20% of our issued and outstanding shares of common stock, have agreed to vote their shares of common stock in favor of the Business Combination. In addition, our Initial Stockholders have agreed to waive their redemption rights with respect to such shares, which will be excluded from the pro rata calculation used to determine the per-share redemption price.

Each redemption of shares of common stock by our public stockholders will reduce the amount in the Trust Account. The Merger Agreement provides that SomaLogic’s obligation to consummate the Business Combination is subject to the condition that that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses. This condition to closing in the Merger Agreement is for the sole benefit of, and may be waived by, SomaLogic. If, as a result of redemptions of common stock by our public stockholders, this condition is not met (or waived by SomaLogic), then SomaLogic may elect not to consummate the Business Combination. In addition, in no event will we redeem shares of our common stock in an amount that would result in the Company’s failure to have net tangible assets equaling or exceeding $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). Holders of our outstanding public warrants do not have redemption rights in connection with the Business Combination. Unless otherwise specified, the information in this proxy statement/prospectus assumes that none of our public stockholders exercise their redemption rights with respect to their shares of common stock.

In connection with the Business Combination, the Company entered into the Subscription Agreements (as defined above) with the PIPE Investors, pursuant to which, among other things, the Company agreed to issue and sell to the PIPE Investors, in private placements to close immediately prior to the Closing, an aggregate of 37,500,000 shares of common stock at $10.00 per share, for an aggregate purchase price of $375,000,000.

A majority of the voting power of all outstanding shares of capital stock of the Company entitled to vote must be present in person or by proxy to constitute a quorum for the transaction of business at the Special Meeting. The Board recommends that you vote “FOR” each of these proposals.

 

Table of Contents

IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS. TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST (I) IF YOU HOLD SHARES OF OUR CLASS A COMMON STOCK THROUGH UNITS, ELECT TO SEPARATE YOUR UNITS INTO THE UNDERLYING SHARES OF OUR CLASS A COMMON STOCK AND PUBLIC WARRANTS PRIOR TO EXERCISING YOUR REDEMPTION RIGHTS WITH RESPECT TO THE PUBLIC SHARES, (II) SUBMIT A WRITTEN REQUEST, INCLUDING THE LEGAL NAME, TELEPHONE NUMBER AND ADDRESS OF THE BENEFICIAL OWNER OF THE SHARES FOR WHICH REDEMPTION IS REQUESTED, TO THE TRANSFER AGENT THAT YOUR PUBLIC SHARES BE REDEEMED FOR CASH AND (III) DELIVER YOUR SHARES OF OUR CLASS A COMMON STOCK TO THE TRANSFER AGENT, PHYSICALLY OR ELECTRONICALLY USING THE DTC’S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM, IN EACH CASE, IN ACCORDANCE WITH THE PROCEDURES AND DEADLINES DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS. IF THE BUSINESS COMBINATION IS NOT CONSUMMATED, THEN THE PUBLIC SHARES WILL NOT BE REDEEMED FOR CASH. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. SEE THE SECTION ENTITLED “SPECIAL MEETING OF COMPANY STOCKHOLDERS — REDEMPTION RIGHTS” IN THIS PROXY STATEMENT/PROSPECTUS FOR MORE SPECIFIC INSTRUCTIONS.

 

By Order of the Board of Directors,

   

/s/ Eli Casdin

   

Eli Casdin

   

Chief Executive Officer

New York, New York

   

              , 2021

   

 

Table of Contents

ABOUT THIS DOCUMENT

This document, which forms part of a registration statement on Form S-4 filed with the SEC by CMLS II, constitutes a prospectus of CMLS II under Section 5 of the Securities Act of 1933, as amended (the “Securities Act”), with respect to the shares of common stock of CMLS II to be issued to SomaLogic’s stockholders under the Merger Agreement. This document also constitutes a proxy statement of CMLS II under Section 14(a) of the Exchange Act.

You should rely only on the information contained or incorporated by reference into this proxy statement/prospectus. No one has been authorized to provide you with information that is different from that contained in, or incorporated by reference into, this proxy statement/prospectus. This proxy statement/prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this proxy statement/prospectus is accurate as of any date other than that date. You should not assume that the information incorporated by reference into this proxy statement/prospectus is accurate as of any date other than the date of such incorporated document. Neither the mailing of this proxy statement/prospectus to CMLS II stockholders nor the issuance by CMLS II of its common stock in connection with the Business Combination will create any implication to the contrary.

Information contained in this proxy statement/prospectus regarding CMLS II has been provided by CMLS II and information contained in this proxy statement/prospectus regarding SomaLogic has been provided by SomaLogic.

This proxy statement/prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities, or the solicitation of a proxy, in any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.

 

Table of Contents

TABLE OF CONTENTS

 

Page

SUMMARY TERM SHEET

 

1

FREQUENTLY USED TERMS

 

6

QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE SPECIAL MEETING

 

10

SUMMARY OF THE PROXY STATEMENT/PROSPECTUS

 

25

SELECTED HISTORICAL FINANCIAL INFORMATION OF THE COMPANY

 

40

SELECTED HISTORICAL FINANCIAL INFORMATION OF SOMALOGIC

 

41

SUMMARY UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

42

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

45

RISK FACTORS

 

47

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

109

COMPARATIVE SHARE INFORMATION

 

118

SPECIAL MEETING OF COMPANY STOCKHOLDERS

 

120

PROPOSAL NO. 1 — THE BUSINESS COMBINATION PROPOSAL

 

127

PROPOSAL NO. 2 — THE NASDAQ STOCK ISSUANCE PROPOSAL

 

173

PROPOSAL NO. 3 — THE INCENTIVE PLAN PROPOSAL

 

176

PROPOSAL NO. 4 — THE ESPP PROPOSAL

 

182

PROPOSAL NO. 5 — THE CHARTER AMENDMENT PROPOSAL

 

186

PROPOSAL NO. 6 — THE ADJOURNMENT PROPOSAL

 

188

INFORMATION ABOUT THE COMPANY

 

189

THE COMPANY’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

202

SOMALOGIC’S BUSINESS

 

205

SOMALOGIC’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

242

EXECUTIVE COMPENSATION OF SOMALOGIC

 

258

MANAGEMENT AFTER THE BUSINESS COMBINATION

 

265

DESCRIPTION OF SECURITIES

 

273

BENEFICIAL OWNERSHIP OF SECURITIES

 

287

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

292

MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION

 

299

LEGAL MATTERS

 

300

EXPERTS

 

300

DELIVERY OF DOCUMENTS TO STOCKHOLDERS

 

301

CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS

 

302

STOCKHOLDER PROPOSALS AND NOMINATIONS

 

306

STOCKHOLDER COMMUNICATIONS

 

308

WHERE YOU CAN FIND MORE INFORMATION

 

309

INDEX TO FINANCIAL STATEMENTS

 

F-1

     

ANNEX A — MERGER AGREEMENT

 

A-1

ANNEX B — OPINION OF HOULIHAN LOKEY CAPITAL, INC.

 

B-1

ANNEX C — INCENTIVE PLAN

 

C-1

ANNEX D — ESPP

 

D-1

ANNEX E — FORM OF A&R CERTIFICATE OF INCORPORATION

 

E-1

ANNEX F — FORM OF AMENDED AND RESTATED BYLAWS

 

F-1

ANNEX G — FORFEITURE AGREEMENT

 

G-1

ANNEX H — STOCKHOLDER SUPPORT AGREEMENT

 

H-1

ANNEX I — SPONSOR SUPPORT AGREEMENT

 

I-1

ANNEX J — SUBSCRIPTION AGREEMENT

 

J-1

i

Table of Contents

SUMMARY TERM SHEET

This summary term sheet, together with the sections entitled “Questions and Answers About the Proposals for Stockholders” and “Summary of the Proxy Statement/Prospectus,” summarizes certain information contained in this proxy statement/prospectus, but does not contain all of the information that is important to you. You should carefully read this entire proxy statement/prospectus, including the attached Annexes, for a more complete understanding of the matters to be considered at the Special Meeting. In addition, for definitions used commonly throughout this proxy statement/prospectus, including this summary term sheet, please see the section entitled “Frequently Used Terms.”

•        CM Life Sciences II Inc., a Delaware corporation, which we refer to as “we,” “us,” “our,” “CMLS II” or the “Company,” is a special purpose acquisition company (“SPAC”) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

•        There are currently 34,500,000 shares of Class A and Class B common stock, par value $0.0001 per share, of the Company, issued and outstanding, consisting of (i) 27,600,000 public shares, and (ii) 6,900,000 Founder Shares held by our Initial Stockholders (“Founder Shares”). There are currently no shares of Company preferred stock issued and outstanding. In addition, we have 5,520,000 public warrants to purchase common stock (originally sold as part of the units issued in our IPO) outstanding along with 5,013,333 private placement warrants issued to our Sponsor in a private placement concurrently with our IPO. Each warrant entitles its holder to purchase one share of our Class A common stock at an exercise price of $11.50 per whole share, to be exercised only for a whole number of shares of our Class A common stock. The warrants will become exercisable 30 days after the completion of the Business Combination, and they expire five years after the completion of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. Once the warrants become exercisable, the Company may redeem the outstanding public warrants at a price of $0.01 per warrant, if the last reported sales price of the Company’s Class A common stock equals or exceeds $18.00 per share for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which we give notice of such redemption and provided certain other conditions are met. For more information regarding the public warrants, please see the section entitled “Description of Securities.”

•        SomaLogic is a commercial stage proteomics company and has historically served over 300 pharmaceutical and research customers and collaborators. SomaLogic’s pioneering technology platform is uniquely capable of becoming a universal proteomics solution. Proprietary aptamers, which are target specific oligonucleotides, facilitate both broad and precise protein measurements. As of April 30, 2021, SomaScan® assay measures 7,000 protein target measurements in a single sample, with high specificity, low variance and high reproducibility, enabling the possibility of faster, more precise drug discovery for researchers. The SomaSignal tests, one of the industry’s leading clinical proteomic diagnostic applications, which provide additional insights to a wide customer base, are a combination of artificial intelligence and machine learning powered bioinformatics algorithms operated in tandem with the SomaLogic’s database of over 450,000 samples. Findings using this patented technology have been published by SomaLogic or collaborators in more than 250 scientific and clinical manuscripts with some of the leading key opinion leaders (“KOLs”).

•        Under the Merger Agreement, CMLS II has agreed to acquire all of the outstanding equity interests of SomaLogic for at least $1.25 billion in aggregate consideration consisting of 125,000,000 shares of CMLS II Class A common stock (assuming no cash elections will be made by SomaLogic stockholders) and up to an additional 5,000,000 shares of CMLS II Class A common stock pursuant to the Earn-Out Shares. Subject to the terms and conditions of the Merger Agreement, at the Effective Time, and as further described in this proxy statement/prospectus, each share of SomaLogic stock other than Excluded Shares and Dissenting Shares (as defined in the Merger Agreement) that is issued and outstanding immediately prior to the Effective Time will be cancelled and automatically deemed for all purposes to represent the right to receive a portion of the total consideration, with each SomaLogic’s stockholder (as applicable) being entitled to receive: (a) if such stockholder has made a cash election as set forth and in accordance with the terms of the Merger Agreement, a portion of the specified aggregate amount of cash consideration payable under the terms of the Merger Agreement (such aggregate amount not to exceed $50,000,000) and pursuant to the terms of such stockholder’s cash election; (b) a number of shares of Class A Common

1

Table of Contents

Stock equal to the quotient of: (i) (A) the product of (x) such stockholder’s total shares of SomaLogic stock (with the SomaLogic common stock and preferred stock (determined on an as-converted basis) included as a single class) multiplied by (y) the per share amount calculated in accordance with the Merger Agreement minus (B) the amount of cash payable to such stockholder pursuant to its cash election, if any, divided by (ii) $10.00; and (c) such stockholder’s earn-out pro rata share of any Earn-Out Shares to which such stockholder is entitled pursuant to the terms of the Merger Agreement.

Following the closing of the Business Combination, and as additional consideration for the Merger and the other transactions, if during the Earn-Out Period, the Triggering Event occurs, then we will deliver or cause to be delivered to each applicable SomaLogic stockholder in accordance with such stockholder’s respective earn-out pro rata share (other than holders of Dissenting Shares, as defined in the Merger Agreement), and Earn-Out Service Provider (in accordance with its respective earn-out pro rata share and, in the case of the Earn-Out Service Providers, in accordance with the terms of the applicable earn-out award agreement), the Earn-Out Shares. Such issuance shall be upon the terms and subject to the conditions set forth in the Merger Agreement and the other transaction agreements and, in the case of the Earn-Out Service Providers, subject to the additional requirements set forth in the Merger Agreement and the applicable earn-out award agreement.

•        In connection with the Business Combination, CMLS II entered into the Subscription Agreements, each dated as of March 28, 2021, with the PIPE Investors, including certain stockholders of SomaLogic and certain affiliates of our Sponsor, pursuant to which, among other things, CMLS II agreed to issue and sell to the PIPE Investors, in private placements to close immediately prior to the Closing, an aggregate of 37,500,000 shares of CMLS II Class A common stock at $10.00 per share, for an aggregate purchase price of $375,000,000 (“PIPE Investment”).

•        It is anticipated that, upon completion of the Business Combination: (i) the Company’s public stockholders (other than the PIPE Investors) will retain an ownership interest, in the aggregate, of approximately 14.7% of the outstanding shares of the post-combination company; (ii) the PIPE Investors will own, in the aggregate, approximately 19.9% of the outstanding shares of the post-combination company (such that public stockholders, including PIPE Investors (including the affiliates of our Sponsor), will own, in the aggregate, approximately 34.6% of the outstanding shares of the post-combination company); (iii) our Initial Stockholders (including our Sponsor) will own, in the aggregate, approximately 3.7% of the outstanding shares of the post-combination company; and (iv) the former SomaLogic stockholders are expected to hold, in the aggregate, approximately 61.7% of the outstanding shares of the post-combination company. Refer to the pro forma post-combination company common stock issued and outstanding immediately after the Business Combination and PIPE Investment in the section entitled “Unaudited Pro Forma Condensed Combined Financial Information.”

Upon the Effective Time, each outstanding option to purchase SomaLogic common stock will be rolled over into options to purchase Company common stock in accordance with the terms of the Merger Agreement.

The ownership percentages with respect to the post-combination company following the Business Combination and PIPE Investment are based on aggregate Merger Consideration of 125,000,000 shares of CMLS II Class A Common Stock (assuming no cash elections will be made by SomaLogic stockholders) and assume 116,013,417 shares will be issued at Closing to current holders of issued and outstanding shares of SomaLogic stock, but does not include the portion of the Merger Consideration that will be allocated to shares underlying issued and outstanding options to acquire SomaLogic stock (totaling, in aggregate and after giving effect to the implied exchange ratio, 8,986,583 shares of CMLS II Class A common stock, calculated on a treasury stock basis) that may be exercised in the future. This calculation also excludes (x) the issuance of any shares following the completion of the Business Combination under the Incentive Plan or the ESPP, copies of which are attached to this proxy statement/prospectus as Annex C and Annex D, respectively, (y) the issuance of any Earn-Out Shares or (z) shares of CMLS II underlying warrants to purchase common stock of CMLS II that will remain outstanding following the Business Combination. In addition, the ownership percentages assume that no public shares are redeemed by the Company. If the actual facts are different than these assumptions, which they are likely to be, the ownership percentages in the post-combination company will be different from the above stated ownership percentages. For more information, please see the sections entitled “Summary of the Proxy Statement/Prospectus — Impact of

2

Table of Contents

the Business Combination on the Company’s Public Float,” “Unaudited Pro Forma Condensed Combined Financial Information,” “Proposal No. 3 — The Incentive Plan Proposal” and “Proposal No. 4 — The ESPP Proposal.”

•        The Sponsor Support Agreement provides that, our Sponsor will vote their shares of common stock in favor of the Business Combination, be bound by certain other covenants and agreements related to the Business Combination and be bound by certain transfer restrictions with respect to their shares of common stock prior to the closing of the Business Combination.

•        The Forfeiture Agreement provides that, our Sponsor, subject to certain limitations and in accordance with the terms of the agreement, will forfeit up to 33% of its shares of our Class B common stock determined based on the actual exercise of redemption rights by stockholders of our company in connection with the Business Combination.

•        Our management and the Board considered various factors in determining whether to approve the Merger Agreement and the Business Combination. For more information about our decision-making process, see the section entitled “Proposal No. 1  The Business Combination Proposal  CMLS II Board of Directors’ Reasons for the Approval of the Business Combination.”

•        Pursuant to our Current Charter, in connection with the Business Combination, holders of our public shares may elect to have their public shares redeemed for cash at the applicable redemption price per share calculated in accordance with our Current Charter. As of March 31, 2021, the estimated per share redemption price would have been approximately $10.00. If a holder exercises its redemption rights, then such holder will be exchanging its shares of our common stock for cash and will no longer own outstanding shares of the post-combination company. Such a holder will be entitled to receive cash for its public shares only if it properly demands redemption and delivers its shares (either physically or electronically) to our Transfer Agent, Continental Stock Transfer & Trust Company, at least two business days prior to the Special Meeting. Please see the section entitled “Special Meeting of Company Stockholders — Redemption Rights.”

•        In addition to voting on the proposal to adopt the Merger Agreement and approve the transactions contemplated thereunder, including the Business Combination, at the Special Meeting, the stockholders of the Company will be asked to vote on:

Proposal No. 2 — The Nasdaq Stock Issuance Proposal — To approve, for purposes of complying with applicable listing rules of Nasdaq, the issuance of more than 20% of the Company’s outstanding common stock in connection with the Business Combination and Subscription Agreements, including up to 37,500,000 shares of our common stock to the PIPE Investors, which includes affiliates of our Sponsor that subscribed for 5,450,000 shares of common stock, and up to 125,000,000 shares of our common stock to SomaLogic stockholders and up to 5,000,000 Earn-Out Shares;

Proposal No. 3 — The Incentive Plan Proposal — To approve the Incentive Plan, a copy of which is attached to this proxy statement/prospectus as Annex C, including the authorization of the initial share reserve under the Incentive Plan;

Proposal No. 4 — The ESPP Proposal — To approve the ESPP, a copy of which is attached to this proxy statement/prospectus as Annex D, including the authorization of the initial share reserve under the ESPP;

Proposal No. 5 — The Charter Amendment Proposal — To adopt the A&R Certificate of Incorporation in the form attached to the accompanying proxy statement/prospectus as Annex E; and

Proposal No. 6 — The Adjournment Proposal — To approve, if necessary, the adjournment of the Special Meeting to a later date or dates to permit further solicitation and votes of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal. This

3

Table of Contents

proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal.

Please see the sections entitled “Proposal No. 1 — The Business Combination Proposal,” “Proposal No. 2 — The Nasdaq Stock Issuance Proposal,” “Proposal No. 3 — The Incentive Plan Proposal,” “Proposal No. 4 — The ESPP Proposal,” “Proposal No. 5 — The Charter Amendment Proposal,” and “Proposal No. 6 — The Adjournment Proposal.” Proposals in this proxy statement/prospectus (other than the Adjournment Proposal) are conditioned on the approval of the Business Combination Proposal.

•        The Merger Agreement may be terminated at any time prior to the consummation of the Business Combination upon mutual written agreement of the parties thereto, or by the Company or SomaLogic in specified circumstances. For more information about the termination rights under the Merger Agreement, please see the section entitled “Proposal No. 1  The Business Combination Proposal  The Merger Agreement  Termination.”

•        The proposed Business Combination involves numerous risks. For more information about these risks, please see the section entitled “Risk Factors.”

•        In considering the recommendation of our Board to vote in favor of the Business Combination, stockholders should be aware that aside from their interests as stockholders, our Sponsor and its affiliates and certain members of our Board and officers have interests in the Business Combination that are different from, or in addition to, those of other stockholders generally. Our Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination, and in recommending to stockholders that they approve the Business Combination. Stockholders should take these interests into account in deciding whether to approve the Business Combination. These interests include, among other things:

•        the fact that our Initial Stockholders have agreed not to redeem any of the Founder Shares in connection with a stockholder vote to approve the Business Combination;

•        the fact that our Initial Stockholders will retain up to 6,900,000 Founder Shares upon the Closing;

•        the fact that our Initial Stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if we fail to complete an initial business combination by February 25, 2023 or any extended period of time that we may have to consummate an initial business combination as a result of an amendment to our Current Charter (“applicable deadline”);

•        if the Trust Account is liquidated, including in the event we are unable to complete an initial business combination within the required time period, our Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on the liquidation date, by the claims of prospective target businesses with which we have entered into an acquisition agreement or claims of any third party (other than our independent public accountants) for services rendered or products sold to us, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the Trust Account;

•        the continued indemnification of our existing directors and officers and the continuation of our directors’ and officers’ liability insurance after the Business Combination;

•        the fact that Eli Casdin, Kevin Conroy, Troy Cox and Stephen Quake will continue as board members of the post-combination company, and shall be entitled to receive compensation for serving on the board of directors of the post-combination company;

•        the fact that certain entities with which Mr. Casdin is affiliated collectively own approximately 8.6% of SomaLogic’s outstanding stock on an as-converted basis, and Mr. Casdin serves on the board of directors of SomaLogic;

4

Table of Contents

•        the fact that our Sponsor, officers and directors will lose their entire investment in us and will not be reimbursed for any out-of-pocket expenses if an initial business combination is not consummated by the applicable deadline;

•        the fact that the Initial Stockholders (including entities controlled by the Company’s officers and directors) have made an aggregate average investment per share of CMLS II Class B common stock of less than $0.01 as of the consummation of the Company’s IPO, and as a result of the significantly lower investment per share of the Initial Stockholders as compared with the investment per share of the Company’s stockholders, a transaction which results in an increase in the value of the investment of the Initial Stockholders may result in a decrease in the value of the investment of the Company’s public stockholders;

•        the fact that simultaneously with the closing of the IPO, the Company completed the private sale of an aggregate of 5,013,333 warrants at a purchase price of $1.50 per private placement warrant, to the Sponsor and certain of CMLS II’s directors (and/or entities controlled by them) generating gross proceeds to CMLS II of $7,520,000, and if a business combination is not consummated by the applicable deadline, the proceeds from the sale of the private placement warrants will be used to fund the redemption of public shares (subject to the requirements of applicable law), and the private placement warrants will be worthless;

•        the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate;

•        the fact that given the differential in purchase price that our Sponsor paid for the Founder Shares as compared to the price of the units sold in the IPO and the substantial number of shares of post-combination company common stock that our Sponsor will receive upon conversion of the Founder Shares in connection with the Business Combination, our Sponsor and its affiliates may realize a positive on such investments even if other CMLS II stockholders experience a negative rate of return following the Business Combination; and

•        that affiliates of the Sponsor, Casdin Capital LLC and Corvex Management L.P. and Dr. Quake and Mr. Cox, have entered into Subscription Agreements with CMLS II, pursuant to which such affiliates have committed to purchase 2,500,000; 2,500,000; 400,000 and 50,000 shares of common stock in the PIPE Investment, respectively, for an aggregate commitment of approximately $25,000,000; $25,000,000; $4,000,000; $500,000, respectively.

5

Table of Contents

FREQUENTLY USED TERMS

Unless otherwise stated or unless the context otherwise requires, the terms “we,” “us,” “our,” the “Company” and “CMLS II” refer to CM Life Sciences II Inc., a Delaware corporation, and the term “post-combination company” refers to the company following the consummation of the Business Combination. In this proxy statement/prospectus:

Aggregate Transaction Proceeds” means an amount equal to the sum of (i) the aggregate cash proceeds available for release to the Company from the Trust Account in connection with the transactions contemplated by the Merger Agreement (after giving effect to any redemptions of public shares, if any) and (ii) the aggregate cash proceeds actually received by CMLS II with respect to the PIPE Investment.

Aggregate Transaction Proceeds Condition” means the minimum aggregate cash amount that CMLS II must have available from the Aggregate Transaction Proceeds, which amount will not be less than $250,000,000.

A&R Certificate of Incorporation” means the proposed Amended and Restated Certificate of Incorporation of the Company, a form of which is attached hereto as Annex E, which will become the post-combination company’s certificate of incorporation assuming the approval of the Charter Amendment Proposal and consummation of the Business Combination. In case the Charter Amendment Proposal is not approved or the Business Combination is not consummated, the Current Charter will continue to be the certificate of incorporation of the post-combination company.

Business Combination” means the transactions contemplated by the Merger Agreement, including the Merger.

Closing” means the consummation of the Business Combination.

Closing Date” means the closing date of the Business Combination.

CMLS II Board”, “our Board” or the “the Board” means the board of directors of CMLS II.

CMLS II Class A common stock” means the shares of Class A common stock, par value $0.0001 per share, of CMLS II.

CMLS II Class B common stock” means the shares of Class B common stock, par value $0.0001 per share, of CMLS II.

Code” means the Internal Revenue Code of 1986, as amended.

Common Share Price” shall mean the share price equal to the volume weighted average closing sale price of one share of CMLS II Class A common stock as reported on Nasdaq (or the exchange on which the shares of CMLS II Class A common stock are then listed) for a period of at least 20 days out of 30 consecutive trading days ending on the trading day immediately prior to the date of determination (as adjusted as appropriate to reflect any stock splits, reverse stock splits, stock dividends (including any dividend or distribution of securities convertible into CMLS II Class A common stock), extraordinary cash dividend (which adjustment shall be subject to the reasonable mutual agreement of CMLS II and SomaLogic), reorganization, recapitalization, reclassification, combination, exchange of shares or other like change or transaction with respect to CMLS II Class A common stock).

Company common stock” means, collectively, the CMLS II Class A common stock and the CMLS II Class B common stock.

D.F. King” means D.F. King & Co., Inc., proxy solicitor to the Company.

DGCL” means the General Corporation Law of the State of Delaware.

DTC” means The Depository Trust Company.

Earn-Out Period” shall mean the time period between the 13-month anniversary of the Closing and the 24-month anniversary of the Closing (inclusive of the first and last day of such period).

Earn-Out RSU” shall mean the award of restricted stock units in respect of the Earn-Out Shares granted to the Earn-Out Service Providers pursuant to the earn-out award agreement.

6

Table of Contents

Earn-Out Service Provider” shall mean each employee or individual service provider of SomaLogic, in each case whom the SomaLogic Board designates as an Earn-Out Service Provider prior to the Closing and who enters into an earn-out award agreement.

Earn-Out Shares” shall mean 5,000,000 shares of CMLS II Class A common stock (which shall be equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares or other like change or transaction with respect to CMLS II Class A common stock occurring on or after the Closing).

Earn-Out Pro Rata Share” shall mean for each SomaLogic Stockholder, such amount determined in accordance with the following formula and as applied by the CMLS II Board in good faith: (The total number of Earn-Out Shares minus the number of Earn-Out Shares underlying any Earn-Out RSUs that are not forfeited by any recipient thereof) multiplied by (such SomaLogic Stockholder’s pro rata portion of the Closing Number of Securities divided by the total Closing Number of Securities).

Effective Time” means, with respect to the Merger, the time on the Closing Date at which the Merger becomes effective.

ESPP” means the SomaLogic, Inc. Employee Stock Purchase Plan, a copy of which is attached to this proxy statement/prospectus as Annex D, to be approved and adopted by the stockholders of CMLS II pursuant to the ESPP Proposal at the Special Meeting.

Exchange Act” means the Securities Exchange Act of 1934, as amended.

Existing Credit Agreements” means (a) the Amended and Restated Credit Agreement, dated as of December 28, 2017, by and among SomaLogic, the guarantors thereto, the lenders thereto and Madryn Health Partners, L.P., as Administrative Agent (the “Madryn Credit Agreement”), provided, however, that on April 9, 2021, with the consent of the Company, SomaLogic repaid in full all amounts owed under the Madryn Credit Agreement and all related loan documents and security documents have been terminated, (b) the Paycheck Protection Program loan, dated as of April 13, 2020, by and between SomaLogic and JPMorgan Chase Bank, N.A. (on June 21, 2021, JPMorgan Chase Bank, N.A. notified SomaLogic that the loan was 100% forgiven by the U.S. Small Business Administration), and (c) the Fifth Amended and Restated Convertible Promissory Note, dated as of June 28, 2017, by and between SomaLogic and Jane W. Butcher (on July 9, 2021, the convertible debt converted into shares of SomaLogic Class B common stock), in each case as may be amended, amended and restated, restated, supplemented or otherwise modified from time to time.

FASB” means the Financial Accounting Standards Board.

Founder Shares” means the aggregate of 6,900,000 shares of CMLS II Class B common stock held by our Initial Stockholders.

GAAP” means United States generally accepted accounting principles.

HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Incentive Plan” means the SomaLogic, Inc. 2021 Omnibus Incentive Plan, a copy of which is attached to this proxy statement/prospectus as Annex C, to be approved and adopted by the stockholders of CMLS II pursuant to the Incentive Plan Proposal at the Special Meeting.

Initial Stockholders” means the Sponsor, Mr. Conroy, Mr. Cox, Dr. Kelly and Dr. Quake.

Investment Company Act” means the Investment Company Act of 1940, as amended.

IPO” means CMLS II’s initial public offering, consummated on February 25, 2021, through the sale of an aggregate of 27,600,000 units at $10.00 per unit, including the issuance of 3,600,000 units as a result of the underwriter’s exercise of its over-allotment in full.

JOBS Act” means the Jumpstart Our Business Startups Act of 2012.

Merger” means the merger of Merger Sub with and into SomaLogic.

7

Table of Contents

Merger Agreement” means that Merger Agreement, dated as of March 28, 2021, by and among CMLS II, Merger Sub and SomaLogic, a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached to this proxy statement/prospectus as Annex A.

Merger Sub” means S-Craft Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of CMLS II.

Nasdaq” means The Nasdaq Stock Market.

Outside Date” means December 31, 2021.

PIPE Investment” means the issuance of an aggregate of 37,500,000 shares of CMLS II Class A common stock pursuant to the Subscription Agreements to the PIPE Investors immediately prior to the Closing, at a purchase price of $10.00 per share.

PIPE Investors” means the certain institutional and accredited investors who are party to the Subscription Agreements.

Post-combination company” means the surviving corporation resulting from the Merger.

Private placement warrants” means the 5,013,333 private placement warrants issued to our Sponsor and CMLS II’s independent director nominees concurrently with CMLS II’s IPO.

Public shares” means shares of CMLS II Class A common stock included in the units issued in CMLS II’s IPO.

Public stockholders” means the holders of public shares.

Public warrants” means the warrants included in the units issued in the IPO, each of which is exercisable for one share of CMLS II Class A common stock, in accordance with its terms.

Registration Rights Agreement” means the amended and restated registration rights agreement to be entered into as of the Closing by and among CMLS II, the Sponsor, certain affiliates of the Sponsor, and certain stockholders of CMLS II.

Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002.

SEC” means the United States Securities and Exchange Commission.

Securities Act” means the Securities Act of 1933, as amended.

SomaLogic” means SomaLogic, Inc., a Delaware corporation.

SomaLogic Board” means the board of directors of SomaLogic.

SomaLogic Class A common stock” means the shares of Class A common stock, par value $0.01 per share, of SomaLogic.

SomaLogic Class B common stock” means the shares of Class B common stock, par value $0.01 per share, of SomaLogic.

SomaLogic preferred stock” means the shares of Series A preferred stock, par value $0.01 per share, of SomaLogic.

SomaLogic common stock” means, collectively, the SomaLogic Class A common stock and the SomaLogic Class B common stock.

SomaLogic stock” means, collectively, the SomaLogic Class A common stock, the SomaLogic Class B common stock and the SomaLogic preferred stock.

SomaLogic Stockholder Approval” means the approval of the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement by the holders of shares of SomaLogic stock representing a majority of the voting power of SomaLogic, including, without limitation, the approval of the holders of the SomaLogic

8

Table of Contents

preferred stock, SomaLogic Class A common stock and SomaLogic Class B common stock, respectively, including the (y) approval of the holders of SomaLogic preferred stock voting as a separate class and (z) approval of holders of the SomaLogic preferred stock and SomaLogic common stock voting as a single class (on an as converted basis).

SomaLogic Management” means the management of SomaLogic following the Closing.

Sponsor” means CMLS Holdings II LLC, a Delaware limited liability company.

Special Meeting” means the special meeting of the stockholders of CMLS II to consider matters relating to the Business Combination, to be held at              a.m., New York City time, on                 , 2021, in virtual format.

Subscription Agreements” means the subscription agreements, each dated as of March 28, 2021, by and between CMLS II and the PIPE Investors, pursuant to which CMLS II has agreed to issue an aggregate of 37,500,000 shares of CMLS II Class A common stock to the PIPE Investors immediately prior to the Closing at a purchase price of $10.00 per share.

“Transactions” means the Business Combination, as well as the issuance of 37,500,000 shares of CMLS II Class A common stock to the PIPE Investors pursuant to the PIPE Investment immediately prior to the Closing.

Transfer Agent” means Continental Stock Transfer & Trust Company.

Triggering Event” shall mean if the Common Share Price is greater than or equal to $20.00 during the Earn-Out Period.

Trust Account” means the Trust Account of CMLS II that holds the proceeds from CMLS II’s IPO and the private placement of the private placement warrants.

Trust Agreement” means that certain Investment Management Trust Agreement, dated as of February 22, 2021, by and between CMLS II and the Trustee.

Trustee” means Continental Stock Transfer & Trust Company.

Units” means the units of CMLS II, each consisting of one share of CMLS II Class A common stock and one-fifth of one public warrant of CMLS II.

9

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE SPECIAL MEETING

The questions and answers below highlight only selected information from this document and only briefly address some commonly asked questions about the proposals to be presented at the Special Meeting, including with respect to the proposed Business Combination. The following questions and answers do not include all the information that is important to our stockholders. We urge stockholders to carefully read this entire proxy statement/prospectus, including the Annexes and the other documents referred to herein, to fully understand the proposed Business Combination and the voting procedures for the Special Meeting, which will be held on [day], [date] at [time] Eastern time at [virtual meeting link].

Q:     Why am I receiving this proxy statement/prospectus?

A:     Our stockholders are being asked to consider and vote upon a proposal to adopt the Merger Agreement and approve the transactions contemplated thereby, including the Business Combination, among other proposals. We have entered into the Merger Agreement, pursuant to which the Company’s wholly owned subsidiary will merge with and into SomaLogic, with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company. Subject to the terms of the Merger Agreement, at the Effective Time of the Business Combination, each share of SomaLogic stock issued and outstanding immediately prior to the Effective Time of the Business Combination, other than Excluded Shares and Dissenting Shares (as defined in the Merger Agreement), will convert into the Merger Consideration set forth in the Merger Agreement. A composite copy of the Merger Agreement, incorporating the amendments into the text of the initial agreement, is attached to this proxy statement/prospectus as Annex A.

This proxy statement/prospectus and its Annexes contain important information about the proposed Business Combination and the other matters to be acted upon at the Special Meeting. You should read this proxy statement/prospectus and its Annexes carefully and in their entirety.

Your vote is important. You are encouraged to submit your proxy as soon as possible after carefully reviewing this proxy statement/prospectus and its Annexes.

Q:     When is the Special Meeting?

A:     The Special Meeting will be held on [day], [date] at [time] Eastern time at [virtual meeting link]. In light of ongoing developments related to coronavirus (COVID-19), after careful consideration, the Company has determined that the Special Meeting will be a virtual meeting conducted exclusively via live webcast in order to facilitate stockholder attendance and participation while safeguarding the health and safety of our stockholders, directors and management team. You or your proxyholder will be able to attend the virtual Special Meeting online, vote, view the list of stockholders entitled to vote at the Special Meeting and submit questions during the Special Meeting by visiting [virtual meeting link] and using a control number assigned by Continental Stock Transfer & Trust Company. To register and receive access to the virtual meeting, registered stockholders and beneficial stockholders (those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions applicable to them provided in the proxy statement/prospectus. Because the Special Meeting is completely virtual and being conducted via live webcast, stockholders will not be able to attend the meeting in person.

Q:     How can I attend and vote at the Special Meeting?

Any stockholder wishing to attend the virtual meeting should register for the meeting by                 , 2021. To register for the Special Meeting, please follow these instructions as applicable to the nature of your ownership of our common stock:

•        If your shares are registered in your name with Continental Stock Transfer & Trust Company and you wish to attend the Special Meeting, go to [virtual meeting link], enter the 12-digit control number included on your proxy card or notice of the meeting and click on the “Click here to preregister for the online meeting” link at the top of the page. Just prior to the start of the meeting you will need to log back into the meeting site using your control number. Pre-registration is recommended but is not required in order to attend.

10

Table of Contents

•        Beneficial stockholders (those holding shares through a stock brokerage account or by a bank or other holder of record) who wish to attend the Special Meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and e-mail a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Beneficial stockholders who e-mail a valid legal proxy will be issued a 12-digit meeting control number that will allow them to register to attend and participate in the Special Meeting. After contacting Continental Stock Transfer & Trust Company, a beneficial holder will receive an e-mail prior to the meeting with a link and instructions for entering the virtual meeting. Beneficial stockholders should contact Continental Stock Transfer & Trust Company at least five business days prior to the meeting date in order to ensure access.

Q:     What are the specific proposals on which I am being asked to vote on at the Special Meeting?

A:     You are being asked to consider and vote on proposals to:

1.      Proposal No. 1 — The Business Combination Proposal — To approve and adopt the Merger Agreement, a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached to this proxy statement/prospectus as Annex A, and approve the transactions contemplated thereby, including the merger of Merger Sub with and into SomaLogic, with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company, and the issuance of common stock to SomaLogic stockholders as Merger Consideration;

2.      Proposal No. 2 — The Nasdaq Stock Issuance Proposal — To approve, for purposes of complying with applicable listing rules of Nasdaq, the issuance of more than 20% of the Company’s outstanding common stock in connection with the Business Combination and Subscription Agreements, including up to 37,500,000 shares of our common stock to the PIPE Investors, which includes affiliates of our Sponsor that subscribed for 5,450,000 shares of common stock, and up to 125,000,000 shares of our common stock to SomaLogic stockholders and up to 5,000,000 Earn-Out Shares;

3.      Proposal No. 3 — The Incentive Plan Proposal — To approve the Incentive Plan a copy of which is attached to this proxy statement/prospectus as Annex C, including the authorization of the initial share reserve under the Incentive Plan;

4.      Proposal No. 4 — The ESPP Proposal — To approve the ESPP a copy of which is attached to this proxy statement/prospectus as Annex D, including the authorization of the initial share reserve under the ESPP;

5.      Proposal No. 5 — The Charter Amendment Proposal — To adopt the A&R Certificate of Incorporation in the form attached to the accompanying proxy statement/prospectus as Annex E; and

6.      Proposal No. 6 — The Adjournment Proposal — To approve, if necessary, the adjournment of the Special Meeting to a later date or dates to permit further solicitation and votes of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal. This proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal.

Q:     Are the proposals conditioned on one another?

A:     Yes. Under the Merger Agreement, the approval of the condition precedent proposals presented at the Special Meeting is a condition to the consummation of the Business Combination. The adoption of each condition precedent proposal in this proxy statement/prospectus (other than the Adjournment Proposal) is conditioned on the approval of all of the condition precedent proposals. If our stockholders do not approve of each of the condition precedent proposals, the Business Combination may not be consummated. Therefore, approval of the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and the ESPP Proposal are conditioned upon stockholders’ approval of the Business Combination Proposal. Moreover, the transactions contemplated by the Merger Agreement will be consummated only if the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and ESPP Proposal are approved at the Special Meeting.

11

Table of Contents

It is important for you to note that in the event that the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal do not receive the requisite vote for approval, we will not consummate the Business Combination. If we do not consummate the Business Combination and fail to complete an initial business combination by the applicable deadline, we will be required to dissolve and liquidate our Trust Account by returning the then remaining funds in such account to the public stockholders.

Q:     Why is the Company providing stockholders with the opportunity to vote on the Business Combination?

A:     Under our Current Charter, we must provide all holders of public shares with the opportunity to have their public shares redeemed upon the consummation of our initial business combination either in conjunction with a tender offer or in conjunction with a stockholder vote. For business and other reasons, we have elected to provide our stockholders with the opportunity to have their public shares redeemed in connection with a stockholder vote, rather than a tender offer. Therefore, we are seeking to obtain the approval of our stockholders of the Business Combination Proposal in order to allow our public stockholders to effectuate redemptions of their public shares in connection with the Closing. The adoption of the Merger Agreement is required under Delaware law and the approval of the Business Combination is required under our Current Charter. In addition, such approval is also a condition to the Closing under the Merger Agreement.

Q:     What will happen in the Business Combination?

A:     Pursuant to the Merger Agreement, SomaLogic will become a wholly-owned subsidiary of the Company as a result of the Merger of the Company’s wholly owned subsidiary, Merger Sub, with and into SomaLogic, with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company.

Q:     Following the Business Combination, will the Company’s securities continue to trade on a stock exchange?

A:     Yes. We intend to apply to list the post-combination company’s common stock and warrants on Nasdaq under symbols “SLGC” and “SLGCW,” respectively, upon the Closing. Our units will automatically separate into the component securities upon consummation of the Business Combination and, as a result, will no longer trade as a separate security.

Q:     How has the announcement of the Business Combination affected the trading price of the Company’s common stock?

A:     On March 26, 2021, the trading date before the public announcement of the Business Combination, the Company’s units closed at $11.64. On such date, the Company’s common stock and warrants did not trade separately. On [•], 2021, the trading date immediately prior to the date of this proxy statement/prospectus, the Company’s units, common stock and warrants closed at $[•], $[•] and $[•], respectively.

Q:     How will the Business Combination impact the shares of the Company outstanding after the Business Combination?

A:     After the Business Combination and the consummation of the transactions contemplated thereby, including the PIPE Investment, the amount of common stock outstanding will increase by approximately 456.5% to approximately 192 million shares of common stock (assuming that no shares of common stock are redeemed and SomaLogic stockholders elect to receive all $50 million in cash). Additional shares of common stock may be issuable in the future as a result of the issuance of additional shares that are not currently outstanding, including the issuance of shares of common stock upon exercise or settlement of the public warrants, private placement warrants, Earn-Out Shares, options and Earn-Out RSUs issued in connection with the Business Combination after the Business Combination. The issuance and sale of such shares in the public market could adversely impact the market price of our common stock, even if our business is doing well.

Q:     Is the Business Combination the first step in a “going private” transaction?

A:     No. The Company does not intend for the Business Combination to be the first step in a “going private” transaction. One of the primary purposes of the Business Combination is to provide a platform for SomaLogic to access the U.S. public markets.

12

Table of Contents

Q:     Will the management of SomaLogic change in the Business Combination?

A:     We anticipate that all of the executive officers of SomaLogic serving as of the date hereof will remain with the post-combination company. The current directors of the Company will resign at the time of the Business Combination, other than Mr. Conroy, Mr. Cox and Dr. Quake, who have been nominated by CMLS II, subject to the approval of the SomaLogic Board, to serve as directors of the post-combination company upon completion of the Business Combination, and Eli Casdin, who has been nominated by SomaLogic to serve as a director of the post-combination company upon completion of the Business Combination. The remaining director nominees will be designated by SomaLogic in accordance with the terms of the Merger Agreement. Please see the section entitled “Management After the Business Combination.”

Q:     What equity stake will current stockholders of the Company, PIPE Investors and the SomaLogic stockholders hold in the post-combination company after the Closing?

A:     It is anticipated that, upon completion of the Business Combination: (i) the Company’s public stockholders (other than the PIPE Investors) will retain an ownership interest, in the aggregate, of approximately 14.7% of the outstanding shares of the post-combination company; (ii) the PIPE Investors will own, in the aggregate, approximately 19.9% of the outstanding shares of the post-combination company (such that public stockholders, including PIPE Investors (including the affiliates of our Sponsor), will own, in the aggregate, approximately 34.6% of the outstanding shares of the post-combination company); (iii) our Initial Stockholders (including our Sponsor) will own, in the aggregate, approximately 3.7% of the outstanding shares of the post-combination company; and (iv) the former SomaLogic stockholders are expected to hold, in the aggregate, approximately 61.7% of the outstanding shares of the post-combination company. Refer to the pro forma post-combination company common stock issued and outstanding immediately after the Business Combination and PIPE Investment in the section entitled “Unaudited Pro Forma Condensed Combined Financial Information”.

The ownership percentages with respect to the post-combination company following the Business Combination and PIPE Investment are based on aggregate Merger Consideration of 125,000,000 shares of CMLS II Class A Common Stock (assuming no cash elections will be made by SomaLogic stockholders) and assume 116,013,417 shares will be issued at Closing to current holders of issued and outstanding shares of SomaLogic stock, but does not include the portion of the Merger Consideration that will be allocated to shares underlying issued and outstanding options to acquire SomaLogic stock (totaling, in aggregate and after giving effect to the implied exchange ratio, 8,986,583 shares of CMLS II Class A common stock, calculated on a treasury stock basis) that may be exercised in the future. This calculation also excludes (x) the issuance of any shares following the completion of the Business Combination under the Incentive Plan or the ESPP, copies of which are attached to this proxy statement/prospectus as Annex C and Annex D, respectively, (y) the issuance of any Earn-Out Shares or (z) shares of CMLS II underlying warrants to purchase common stock of CMLS II that will remain outstanding following the Business Combination. In addition, the ownership percentages assume that no public shares are redeemed by the Company. If the actual facts are different than these assumptions, which they are likely to be, the ownership percentages in the post-combination company will be different from the above stated ownership percentages. For more information, please see the sections entitled “Summary of the Proxy Statement/Prospectus — Impact of the Business Combination on the Company’s Public Float,” “Unaudited Pro Forma Condensed Combined Financial Information,” “Proposal No. 3 — The Incentive Plan Proposal” and “Proposal No. 4 — The ESPP Proposal.”

Q:     Will the Company obtain new financing in connection with the Business Combination?

A:     Yes. The PIPE Investors have agreed to purchase 37,500,000 shares of common stock, in the aggregate, for $375,000,000 of gross proceeds, pursuant to the Subscription Agreements. The Subscription Agreements are contingent upon, among other things, stockholder approval of the Business Combination Proposal and the Closing. See the section entitled “Proposal No. 1 — The Business Combination Proposal — Related Agreements — Subscription Agreements.” The Company does not currently anticipate obtaining any new debt financing to fund the Business Combination.

Q:     What conditions must be satisfied to complete the Business Combination?

A:     There are a number of closing conditions in the Merger Agreement, including the approval by the stockholders of the Company of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive

13

Table of Contents

Plan Proposal and the ESPP Proposal. For a summary of the conditions that must be satisfied or waived prior to completion of the Business Combination, please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement.”

Q:     Are there any arrangements to help ensure that the Company will have sufficient funds, together with the proceeds in its Trust Account and from the PIPE Investment, to fund the aggregate purchase price?

A:     Unless waived by SomaLogic, the Merger Agreement provides that SomaLogic’s obligation to consummate the Business Combination is conditioned on the funds in the Trust Account, together with the funding of any amounts payable under the Subscription Agreements, being equal to no less than an aggregate amount of $250,000,000 after payment of redemptions and Company and SomaLogic transaction expenses. The PIPE Investors have agreed to purchase approximately 37,500,000 shares of common stock at $10.00 per share for gross proceeds to the Company of approximately $375,000,000 pursuant to Subscription Agreements entered into at the signing of the Merger Agreement. The PIPE Investment is contingent upon, among other things, stockholder approval of the Business Combination Proposal and the Closing.

The Company will use the proceeds of the PIPE Investment, together with the funds in the Trust Account, to pay certain fees, costs and expenses (including regulatory fees, legal fees, accounting fees, printer fees and other professional fees) that were incurred by the Company and other parties to the Merger Agreement in connection with the transactions contemplated by the Merger Agreement, including the Business Combination, and pursuant to the terms of the Merger Agreement.

Q:     Why is the Company proposing the Nasdaq Stock Issuance Proposal?

A:     We are proposing the Nasdaq Stock Issuance Proposal in order to comply with Nasdaq Listing Rules 5635(a) and (d), which require stockholder approval of certain transactions that result in the issuance of 20% or more of the outstanding voting power or shares of common stock outstanding before the issuance of stock or securities.

In connection with the Business Combination, we expect to issue (i) up to 125,000,000 shares of common stock in the Business Combination plus up to 5,000,000 Earn-Out Shares, and (ii) approximately 37,500,000 shares of common stock in the PIPE Investment. Because we may issue 20% or more of our outstanding common stock when considering together the Stock Consideration and the PIPE Investment, we are required to obtain stockholder approval of such issuance pursuant to Nasdaq Listing Rules 5635(a) and (d). For more information, please see the section entitled “Proposal No. 2 — The Nasdaq Stock Issuance Proposal.”

Q:     Why is the Company proposing the Incentive Plan Proposal?

A:     The purpose of the Incentive Plan Proposal is to further align the interests of the eligible participants with those of stockholders by providing long- term incentive compensation opportunities tied to the performance of the post-combination company. Please see the section entitled “Proposal No. 3 — The Incentive Plan Proposal” for additional information.

Q:     Why is the Company proposing the ESPP Proposal?

A:     The purpose of the ESPP Proposal is to provide eligible employees with an opportunity to increase their proprietary interest in the success of the Company by purchasing common stock on favorable terms and to pay for such purchases through payroll deductions. The Company believes by providing eligible employees with an opportunity to increase their proprietary interest in the success of the Company, the ESPP will motivate participants to offer their maximum effort to the Company and help focus them on the creation of long-term value consistent with the interests of the Company’s stockholders. For more information about the ESPP, please see the section entitled “Proposal No. 4 — The ESPP Proposal”.

Q:     Why is the Company proposing the Charter Amendment Proposal?

A:     The A&R Certificate of Incorporation that we are asking our stockholders to adopt in connection with the Business Combination provides for certain amendments to our Current Charter. Pursuant to Delaware law, we are required to submit the Charter Amendment Proposal to the Company’s stockholders for adoption. The A&R

14

Table of Contents

Certificate of Incorporation will not be adopted if the Business Combination is not consummated; however, approval of the Charter Amendment Proposal is not a condition to completing the Business Combination. For additional information please see the section entitled “Proposal No. 5 — The Charter Amendment Proposal.

Q:     Why is the Company proposing the Adjournment Proposal?

A:     We are proposing the Adjournment Proposal to allow our Board to adjourn the Special Meeting to a later date or dates to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal, but no other proposal if the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and the ESPP Proposal are approved. Please see the section entitled “Proposal No. 5 — The Adjournment Proposal” for additional information.

Q:     What happens if I sell my shares of common stock before the Special Meeting?

A:     The record date for the Special Meeting is earlier than the date that the Business Combination is expected to be completed. If you transfer your shares of common stock after the record date, but before the Special Meeting, unless the transferee obtains from you a proxy to vote those shares, you will retain your right to vote at the Special Meeting. However, you will not be able to seek redemption of your shares of common stock because you will no longer be able to deliver them for cancellation upon consummation of the Business Combination. If you transfer your shares of common stock prior to the record date, you will have no right to vote those shares at the Special Meeting or redeem those shares for a pro rata portion of the proceeds held in our Trust Account.

Q:     What constitutes a quorum at the Special Meeting?

A:     A majority of the voting power of all outstanding shares of the capital stock of the Company entitled to vote must be present in person or by proxy (which would include presence at the virtual Special Meeting) to constitute a quorum for the transaction of business at the Special Meeting. Abstentions will be counted as present for the purpose of determining a quorum. Our Initial Stockholders, who currently own approximately 20% of our issued and outstanding shares of common stock, will count towards this quorum. In the absence of a quorum, the chairman of the Special Meeting has power to adjourn the Special Meeting. As of the record date for the Special Meeting, 17,250,001 shares of our common stock would be required to achieve a quorum.

Q:     What vote is required to approve the proposals presented at the Special Meeting?

A:     Proposal No. 1 — The Business Combination Proposal:    The approval of the Business Combination Proposal requires the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, a Company stockholder’s failure to vote, as well as an abstention from voting and a broker non-vote, will have no effect on the Business Combination Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established but will have no effect on the Business Combination Proposal. Our Initial Stockholders have agreed to vote their shares of common stock “FOR” the Business Combination Proposal.

Proposal No. 2 — The Nasdaq Stock Issuance Proposal:    The approval of the Nasdaq Stock Issuance Proposal requires the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, under Delaware law, a Company stockholder’s failure to vote, as well as an abstention and broker non-vote, will have no effect on the Nasdaq Stock Issuance Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established. Our Initial Stockholders have agreed to vote their shares of common stock “FOR” the Nasdaq Stock Issuance Proposal.

Proposal No. 3 — The Incentive Plan Proposal:    The approval of the Incentive Plan Proposal requires the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, under Delaware law, a Company stockholder’s failure to vote by proxy, as well as an abstention and broker non-vote, will have no effect on the Incentive Plan Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established. Our Initial Stockholders have agreed to vote their shares of common stock “FOR” the Incentive Plan Proposal.

15

Table of Contents

Proposal No. 4 — The ESPP Proposal:    The approval of the ESPP Proposal requires the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, under Delaware law, a Company stockholder’s failure to vote by proxy, as well as an abstention and broker non-vote, will have no effect on the ESPP Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established. Our Initial Stockholders have agreed to vote their shares of common stock “FOR” the ESPP Proposal.

Proposal No. 5 — The Charter Amendment Proposal:    The approval of the Charter Amendment Proposal requires the affirmative vote of a majority of the outstanding shares of CMLS II common stock present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, a Company stockholder’s failure to vote, as well as an abstention from voting and a broker non-vote, will have the same effect as a vote “AGAINST” such Charter Amendment Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established. Our Initial Stockholders have agreed to vote their shares of common stock “FOR” the Charter Amendment Proposal, however, the Business Combination is not conditioned to approval of the Charter Amendment Proposal. Therefore, if the Charter Amendment Proposal is not approved, the Current Charter will continue to be the certificate of incorporation of the post-combination company.

Proposal No. 6 — The Adjournment Proposal:    The approval of the Adjournment Proposal requires the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy and entitled to vote at the Special Meeting. Accordingly, a Company stockholder’s failure to vote, as well as an abstention from voting and a broker non-vote, will have no effect on the Adjournment Proposal. Abstentions will be counted in connection with the determination of whether a valid quorum is established but will have no effect on the Adjournment Proposal.

Q:     What happens if the Business Combination Proposal is not approved?

A:     If the Business Combination Proposal is not approved and we do not consummate a business combination by the applicable deadline, we will be required to dissolve and liquidate our Trust Account.

Q:     May the Company, its Sponsor or the Company’s directors or officers or their affiliates purchase shares in connection with the Business Combination?

A:     In connection with the stockholder vote to approve the proposed Business Combination, we, our Sponsor, or our directors or officers or their respective affiliates may privately negotiate transactions to purchase shares from stockholders who would have otherwise elected to have their shares redeemed in conjunction with a proxy solicitation pursuant to the proxy rules for a per-share pro rata portion of the Trust Account. None of our directors or officers or their respective affiliates will make any such purchases when they are in possession of any material non-public information not disclosed to the seller or during a restricted period under Regulation M under the Exchange Act. Such a purchase may include a contractual acknowledgement that such selling stockholder, although still the record holder of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights, and could include a contractual provision that directs such selling stockholder to vote such shares in a manner directed by the purchaser. In the event that our Sponsor, directors or officers or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. Any such privately negotiated purchases may be effected at purchase prices that are below or in excess of the per-share pro rata portion of the Trust Account.

Q:     How many votes do I have at the Special Meeting?

A:     Our stockholders are entitled to one vote on each proposal presented at the Special Meeting for each share of common stock held of record as of [•], 2021, the record date for the Special Meeting. As of the close of business on the record date, there were 34,500,000 outstanding shares of our common stock.

16

Table of Contents

Q:     How do I vote?

A:     If you were a stockholder of record on [•], 2021, you may vote by granting a proxy. Specifically, you may vote:

By Mail — You may vote by mail by completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. Votes submitted by mail must be received by 11:59 pm Eastern time on [•], 2021.

•        You should sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity (for example, as guardian, executor, trustee, custodian, attorney or officer of a corporation), indicate your name and title or capacity.

•        We encourage you to sign and return the proxy card even if you plan to attend the Special Meeting so that your shares will be voted if you are unable to attend the Special Meeting.

•        If you receive more than one proxy card, it is an indication that your shares are held in multiple accounts. Please sign and return all proxy cards to ensure that all of your shares are voted.

•        Voting at the Special Meeting — We will be hosting the Special Meeting via live webcast. If you attend the Special Meeting, you may submit your vote at the Special Meeting online at [virtual meeting link], in which case any votes that you previously submitted will be superseded by the vote that you cast at the Special Meeting.

If you hold your shares in street name, you must submit voting instructions to your broker, bank or other nominee. In most instances, you will be able to do this over the Internet, by telephone or by mail. Please refer to information from your bank, broker, or other nominee on how to submit voting instructions.

Q:     What will happen if I abstain from voting or fail to vote at the Special Meeting?

A:     At the Special Meeting, we will count a properly executed proxy marked “ABSTAIN” with respect to a particular proposal as present for purposes of determining whether a quorum is present. For purposes of approval, a failure to vote or an abstention will have no effect on the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal. A failure to vote or an abstention will have the same effect as a vote against the Charter Amendment Proposal.

Q:     What will happen if I sign and return my proxy card without indicating how I wish to vote?

A:     Signed and dated proxies received by us without an indication of how the stockholder intends to vote on a proposal will be voted “FOR” each proposal presented to the stockholders. The proxyholders may use their discretion to vote on any other matters which properly come before the Special Meeting.

Q:     If I am not going to attend the Special Meeting, should I return my proxy card instead?

A:     Yes. Whether you plan to attend the Special Meeting or not, please read the enclosed proxy statement/prospectus carefully. If you are a stockholder of record of our common stock as of the close of business on the record date, you can vote by proxy by mail by following the instructions provided in the enclosed proxy card. Please note that if you are a beneficial owner of our common stock, you may vote by submitting voting instructions to your broker, bank or nominee, or otherwise by following instructions provided by your broker, bank or nominee. Telephone and internet voting may be available to beneficial owners. Please refer to the vote instruction form provided by your broker, bank or nominee.

Q:     What is the difference between a stockholder of record and a “street name” holder?

A:     If your shares are registered directly in your name with the Company’s transfer agent, Continental Stock Transfer & Trust Company, you are considered the stockholder of record with respect to those shares, and access to proxy materials is being provided directly to you. If your shares are held in a stock brokerage account or by a bank or other nominee, then you are considered the beneficial owner of those shares, which are considered to be held in “street name.” Access to proxy materials is being provided to you by your broker, bank or other nominee who is considered the stockholder of record with respect to those shares.

17

Table of Contents

Q:     If my shares are held in “street name,” will my broker, bank or nominee automatically vote my shares for me?

A:     No. Under the rules of various national and regional securities exchanges, your broker, bank, or nominee cannot vote your shares with respect to non-routine matters unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank, or nominee.

We believe that all of the proposals presented to the stockholders at this Special Meeting will be considered non-routine and, therefore, your broker, bank, or nominee cannot vote your shares without your instruction on any of the proposals presented at the Special Meeting. Accordingly, if your broker submits a proxy for your shares, but you do not submit voting instructions on the proposals, your broker, bank, or other nominee may deliver a proxy card expressly indicating that it is NOT voting your shares; this indication that a broker, bank, or nominee is not voting your shares is referred to as a “broker non-vote.” Broker non-votes will not be counted for the purposes of determining the existence of a quorum or for purposes of determining the number of votes cast at the Special Meeting. Your bank, broker, or other nominee can vote your shares only if you provide instructions on how to vote. You should instruct your broker to vote your shares in accordance with directions you provide.

Q:     How will a broker non-vote impact the results of each proposal?

A:     Broker non-votes will not have any effect on the outcome of any of the proposals.

Q:     May I change my vote after I have returned my signed proxy card or voting instruction form?

A:     Yes. If you are a holder of record of our common stock as of the close of business on the record date, whether you vote by mail, you can change or revoke your proxy before it is voted at the Special Meeting by:

•        delivering a signed written notice of revocation to our Secretary at CM Life Sciences II Inc., 667 Madison Ave, New York, NY 10065, bearing a date later than the date of the proxy, stating that the proxy is revoked;

•        signing and delivering a new proxy, relating to the same shares and bearing a later date; or

•        attending and voting at the Special Meeting and voting, although attendance at the Special Meeting will not, by itself, revoke a proxy.

If you are a beneficial owner of our common stock as of the close of business on the record date, you must follow the instructions of your broker, bank or other nominee to revoke or change your voting instructions.

Q:     What should I do if I receive more than one set of voting materials?

A:     You may receive more than one set of voting materials, including multiple copies of this proxy statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast your vote with respect to all of your shares.

Q:     How will the Company’s Sponsor, directors and officers vote?

A:     Prior to our IPO, we entered into agreements with our Sponsor and each of our directors and officers, pursuant to which each agreed to vote any shares of common stock owned by them in favor of the Business Combination Proposal. None of our Sponsor, directors or officers has purchased any shares of our common stock during or after our IPO and, as of the date of this proxy statement/prospectus, neither we nor our Sponsor, directors or officers have entered into agreements, and are not currently in negotiations, to purchase shares prior to the consummation of the Business Combination. Currently, our Initial Stockholders own approximately 20% of our issued and outstanding shares of common stock, including all of the Founder Shares, and will be able to vote all such shares at the Special Meeting.

18

Table of Contents

Q:     What interests do the Sponsor and the Company’s current officers and directors have in the Business Combination?

A:     Our Sponsor and certain members of our Board and officers have interests in the Business Combination that are different from or in addition to (and which may conflict with) your interests. You should take these interests into account in deciding whether to approve the Business Combination. These interests include:

•        the fact that our Initial Stockholders have agreed not to redeem any of the Founder Shares in connection with a stockholder vote to approve the Business Combination;

•        the fact that our Initial Stockholders will retain up to 6,900,000 Founder Shares upon the Closing;

•        the fact that our Initial Stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if we fail to complete an initial business combination by the applicable deadline;

•        if the Trust Account is liquidated, including in the event we are unable to complete an initial business combination within the required time period, our Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on the liquidation date, by the claims of prospective target businesses with which we have entered into an acquisition agreement or claims of any third party (other than our independent public accountants) for services rendered or products sold to us, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the Trust Account;

•        the continued indemnification of our existing directors and officers and the continuation of our directors’ and officers’ liability insurance after the Business Combination;

•        the fact that Eli Casdin, Kevin Conroy, Troy Cox and Stephen Quake will continue as board members of the post-combination company, and shall be entitled to receive compensation for serving on the board of directors of the post-combination company;

•        the fact that certain entities with which Mr. Casdin is affiliated collectively own approximately 8.6% of SomaLogic’s outstanding stock on an as-converted basis, and Mr. Casdin serves on the board of directors of SomaLogic;

•        the fact that our Sponsor, officers and directors will lose their entire investment in us and will not be reimbursed for any out-of-pocket expenses if an initial business combination is not consummated by the applicable deadline;

•        the fact that the Initial Stockholders (including entities controlled by the Company’s officers and directors) have made an aggregate average investment per share of CMLS II Class B common stock of less than $0.01 as of the consummation of the Company’s IPO, and as a result of the significantly lower investment per share of the Initial Stockholders as compared with the investment per share of the Company’s stockholders, a transaction which results in an increase in the value of the investment of the Initial Stockholders may result in a decrease in the value of the investment of the Company’s public stockholders;

•        the fact that simultaneously with the closing of the IPO, the Company completed the private sale of an aggregate of 5,013,333 warrants at a purchase price of $1.50 per private placement warrant, to the Sponsor and certain of the Company’s directors (and/or entities controlled by them) generating gross proceeds to the Company of $7,520,000, and if a business combination is not consummated by the applicable deadline, the proceeds from the sale of the private placement warrants will be used to fund the redemption of public shares (subject to the requirements of applicable law), and the private placement warrants will be worthless;

•        the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate;

•        the fact that given the differential in purchase price that our Sponsor paid for the Founder Shares as compared to the price of the units sold in the IPO and the substantial number of shares of post-combination company common stock that our Sponsor will receive upon conversion of the Founder Shares in connection with the Business Combination, our Sponsor and its affiliates may realize a positive on such investments even if other CMLS II stockholders experience a negative rate of return following the Business Combination; and

19

Table of Contents

•        that affiliates of the Sponsor, Casdin Capital LLC and Corvex Management L.P. and Dr. Quake and Mr. Cox, have entered into Subscription Agreements with the Company, pursuant to which such affiliates have committed to purchase 2,500,000; 2,500,000; 400,000 and 50,000 shares of common stock in the PIPE Investment, respectively, for an aggregate commitment of approximately $25,000,000; $25,000,000; $4,000,000; $500,000, respectively.

These interests may influence our directors in making their recommendation that you vote in favor of the approval of the Business Combination.

Q:     What happens if I vote against the Business Combination Proposal?

A:     If you vote against the Business Combination Proposal but the Business Combination Proposal still obtains the affirmative vote of a majority of the votes cast by holders of our common stock represented in person or by proxy and entitled to vote at the Special Meeting, then the Business Combination Proposal will be approved and, assuming the approval of the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and the ESPP Proposal and the satisfaction or waiver of the other conditions to closing, the Business Combination will be consummated in accordance with the terms of the Merger Agreement.

If you vote against the Business Combination Proposal and the Business Combination Proposal does not obtain the affirmative vote of a majority of the votes cast by holders of our of common stock represented in person or by proxy and entitled to vote at the Special Meeting, then the Business Combination Proposal will fail and we will not consummate the Business Combination. If we do not consummate the Business Combination, we may continue to try to complete a business combination with a different target business until the applicable deadline. If we fail to complete an initial business combination by the applicable deadline, then we will be required to dissolve and liquidate the Trust Account by returning the then-remaining funds in such account to our public stockholders.

Q:     Do I have redemption rights?

A:     Pursuant to our Current Charter, we are providing our public stockholders with the opportunity to redeem, upon the Closing, shares of common stock for cash equal to the pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account that holds the proceeds of our IPO (including interest not previously released to the Company to pay franchise and income taxes), subject to certain limitations. For illustrative purposes, based on the balance of the Trust Account of approximately $276 million as of March 31, 2021, the estimated per share redemption price would have been approximately $10.00. Public stockholders may elect to redeem their shares even if they vote for the Business Combination. Any request to redeem public shares, once made, may be withdrawn at any time until the deadline for exercising redemption requests and thereafter, with our consent, until the Closing. If we receive valid redemption requests from holders of public shares prior to the redemption deadline, we may, at our sole discretion, following the redemption deadline and until the date of Closing, seek and permit withdrawals by one or more of such holders of their redemption requests. We may select which holders to seek such withdrawals of redemption requests from based on any factors we may deem relevant, and the purpose of seeking such withdrawals may be to increase the funds held in the Trust Account, including where we otherwise would not satisfy the closing condition that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, after the payment of redemptions and satisfaction of Company and SomaLogic transaction expenses.

Our Initial Stockholders have agreed to waive their redemption rights with respect to such shares, which will be excluded from the pro rata calculation used to determine the per-share redemption price.

Each redemption of shares of common stock by our public stockholders will reduce the amount in the Trust Account. The Merger Agreement provides that SomaLogic’s obligation to consummate the Business Combination is subject to the condition that that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses. This condition to closing in the Merger Agreement is for the sole benefit of, and may be waived by, SomaLogic. If, as a result of redemptions of common stock by our public stockholders, this condition is not met (or waived by SomaLogic), then SomaLogic may elect not to consummate the Business Combination. In addition, in no event will we redeem shares of our common stock in an amount that would result in the Company’s failure to have net tangible assets equaling or exceeding $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). Holders

20

Table of Contents

of our outstanding public warrants do not have redemption rights in connection with the Business Combination. Unless otherwise specified, the information in this proxy statement/prospectus assumes that none of our public stockholders exercise their redemption rights with respect to their shares of common stock.

Q:     Can the Initial Stockholders redeem their Founder Shares in connection with consummation of the Business Combination?

A:     No. Our Initial Stockholders, officers and directors have agreed to waive their redemption rights with respect to their shares of common stock in connection with the consummation of our Business Combination. Our Initial Stockholders have also agreed to waive their right to a conversion price adjustment with respect to any shares of our common stock they may hold in connection with the consummation of the Business Combination.

Q:     Is there a limit on the number of shares I may redeem?

A:     We have no specified maximum redemption threshold under our Current Charter. Each redemption of shares of common stock by our public stockholders will reduce the amount in the Trust Account. The Merger Agreement provides that SomaLogic’s obligation to consummate the Business Combination is subject to the condition that that the amount in the Trust Account and the proceeds from the PIPE Investment equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any redemptions and payment of all Company and SomaLogic transaction expenses. This condition to closing in the Merger Agreement is for the sole benefit of, and may be waived by, SomaLogic. If, as a result of redemptions of common stock by our public stockholders, this condition is not met (or waived by SomaLogic), then SomaLogic may elect not to consummate the Business Combination. In addition, in no event will we redeem shares of our common stock in an amount that would result in the Company’s failure to have net tangible assets equaling or exceeding $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). Holders of our outstanding public warrants do not have redemption rights in connection with the Business Combination. Unless otherwise specified, the information in this proxy statement/prospectus assumes that none of our public stockholders exercise their redemption rights with respect to their shares of common stock.

Q:     Is there a limit on the total number of shares that may be redeemed?

A:     Yes. Our Current Charter provides that we may not redeem our public shares in an amount that would result in the Company’s failure to have net tangible assets in excess of $5,000,001 (such that we are not subject to the SEC’s “penny stock” rules) or any greater net tangible asset or cash requirement which may be contained in the Merger Agreement. Other than this limitation, our Current Charter does not provide a specified maximum redemption threshold. In addition, the Merger Agreement provides that the obligation of SomaLogic to consummate the Business Combination is conditioned on the amount in the Trust Account and the proceeds from the PIPE Investment equaling or exceeding $250,000,000, after the payment of redemptions and satisfaction of Company and SomaLogic transaction expenses. In the event the aggregate cash consideration we would be required to pay for all shares of common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the Merger Agreement exceeds the aggregate amount of cash available to us, we may not complete the Business Combination or redeem any shares, all shares of common stock submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate business combination.

Based on the amount of approximately $276 million in our Trust Account as of March 31, 2021, and taking into account the anticipated gross proceeds of approximately $375 million from the PIPE Investment, approximately 27,600,000 shares of common stock may be redeemed and still enable us to have sufficient cash to satisfy the cash closing conditions in the Merger Agreement. We refer to this as the maximum redemption scenario.

Q:     Will how I vote affect my ability to exercise redemption rights?

A:     No. You may exercise your redemption rights whether you vote your shares of common stock for or against, or whether you abstain from voting on the Business Combination Proposal or any other proposal described by this proxy statement/prospectus. As a result, the Merger Agreement can be approved by stockholders who will redeem their shares and no longer remain stockholders, leaving stockholders who choose not to redeem their shares holding shares in a company with a potentially less-liquid trading market, fewer stockholders, potentially less cash and the potential inability to meet the listing standards of Nasdaq.

21

Table of Contents

Q:     How do I exercise my redemption rights?

A:     In order to exercise your redemption rights, you must (i)(a) hold public shares or (b) hold public shares through units and elect to separate your units into the underlying public shares and public warrants prior to exercising your redemption rights with respect to the public shares; and (ii) prior to 5:00 p.m. Eastern time on [•], 2021 (two business days before the Special Meeting) (a) submit a written request to the Transfer Agent that the Company redeem your public shares for cash and (b) deliver your public shares to the Transfer Agent, physically or electronically through DTC. Any demand for redemption, once made, may be withdrawn at any time until the deadline for exercising redemption requests and thereafter, with our consent, until the Closing.

The Transfer Agent’s address is as follows:

Continental Stock Transfer & Trust Company
1 State Street, 30th Floor
New York, New York 10004

Attention: Mark Zimkind
Email: mzimkind@continentalstock.com

Stockholders seeking to exercise their redemption rights and opting to deliver physical certificates should allot sufficient time to obtain physical certificates from the Transfer Agent and time to effect delivery. It is our understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the Transfer Agent. However, we do not have any control over this process and it may take longer than two weeks. Stockholders who hold their shares in street name will have to coordinate with their bank, broker or other nominee to have the shares certificated or delivered electronically.

Stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name” are required to either tender their certificates to our Transfer Agent prior to the date set forth in these proxy materials, or up to two business days prior to the vote on the proposal to approve the Business Combination at the Special Meeting, or to deliver their shares to the Transfer Agent electronically using Depository Trust Company’s (“DTC”) Deposit/Withdrawal At Custodian (“DWAC”) system, at such stockholder’s option. The requirement for physical or electronic delivery prior to the Special Meeting ensures that a redeeming stockholder’s election to redeem is irrevocable once the Business Combination is approved.

There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC system. The Transfer Agent will typically charge a tendering broker a fee and it is in the broker’s discretion whether or not to pass this cost on to the redeeming stockholder. However, this fee would be incurred regardless of whether or not we require stockholders seeking to exercise redemption rights to tender their shares, as the need to deliver shares is a requirement to exercising redemption rights, regardless of the timing of when such delivery must be effectuated.

Q:     What are the U.S. federal income tax consequences of exercising my redemption rights?

A:     The U.S. federal income tax consequences of exercising your redemption rights depends on your particular facts and circumstances. It is possible that you may be treated as selling your public shares for cash and, as a result, recognize capital gain or capital loss. It is also possible that the redemption may be treated as a distribution for U.S. federal income tax purposes depending on the amount of public shares that you own or are deemed to own (including through the ownership of the warrants). Please see the section entitled “Proposal No. 1 — The Business Combination Proposal — Material United States Federal Income Tax Considerations for Public Stockholders Exercising Redemption Rights” for a more detailed discussion of the U.S. federal income tax considerations of an exercise of redemption rights. We urge you to consult your tax advisors regarding the tax consequences of exercising your redemption rights in your particular facts and circumstances.

Q:     What are the material U.S. federal income tax consequences of the Business Combination to me?

A:     Certain material U.S. federal income tax considerations that may be relevant to you in respect of the Business Combination are discussed in more detail in the section entitled “Certain Material U.S. Federal Income Tax Considerations.” The discussion of the U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and is not a complete analysis or description of all of the U.S. federal income tax considerations that are applicable to you in respect of the Business Combination, nor does it address any tax considerations arising under U.S. state or local or non-U.S. tax laws.

22

Table of Contents

TAX MATTERS ARE COMPLICATED, AND THE TAX CONSEQUENCES OF THE BUSINESS COMBINATION WILL DEPEND ON THE FACTS OF YOUR OWN SITUATION. YOU SHOULD CONSULT YOUR TAX ADVISOR AS TO THE SPECIFIC TAX CONSEQUENCES OF THE BUSINESS COMBINATION TO YOU IN YOUR PARTICULAR CIRCUMSTANCES.

Q:     If I am a Company warrant holder, can I exercise redemption rights with respect to my public warrants?

A:     No. The holders of our public warrants have no redemption rights with respect to our public warrants.

Q:     Do I have appraisal rights if I object to the proposed Business Combination?

A:     No. Appraisal rights are not available to holders of our common stock in connection with the Business Combination.

Q:     What happens to the funds held in the Trust Account upon consummation of the Business Combination?

A:     The funds held in the Trust Account (together with the proceeds from the PIPE Investment) will be used to pay certain fees, costs and expenses (including regulatory fees, legal fees, accounting fees, printer fees and other professional fees) that were incurred by the Company and other parties to the Merger Agreement in connection with the transactions contemplated by the Merger Agreement, including the Business Combination, and pursuant to the terms of the Merger Agreement.

Q:     What happens if the Business Combination is not consummated?

A:     There are certain circumstances under which the Merger Agreement may be terminated. Please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement” for information regarding the parties’ specific termination rights.

If we do not consummate the Business Combination, we may continue to try to complete a business combination with a different target business until the applicable deadline. If we fail to complete an initial business combination by the applicable deadline, then we will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem our public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest not previously released to the Company to pay its franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish our public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law; and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our Board, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the IPO price per unit in the IPO. Please see the section entitled “Risk Factors — Risks Related to CMLS II and the Business Combination.”

Holders of our Founder Shares have waived any right to any liquidation distribution with respect to such shares and the underwriters of our IPO agreed to waive their rights to the business combination marketing fee held in the Trust Account in the event we do not complete our initial business combination within the required period. In addition, if we fail to complete a business combination by the applicable deadline, there will be no redemption rights or liquidating distributions with respect to our outstanding warrants, which will expire worthless.

Q:     When is the Business Combination expected to be completed?

A:     The closing of the Business Combination is expected to take place on or prior to the third business day following the satisfaction or waiver of the conditions described below in the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Conditions to Closing the Business Combination.” The closing is expected to occur in the [third] quarter of 2021. The Merger Agreement may be terminated by the Company or SomaLogic if the Closing has not occurred by December 31, 2021.

For a description of the conditions to the completion of the Business Combination, please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Conditions to Closing the Business Combination.

23

Table of Contents

Q:     What do I need to do now?

A:     You are urged to carefully read and consider the information contained in this proxy statement/prospectus, including the Annexes, and to consider how the Business Combination will affect you as a stockholder. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus and on the enclosed proxy card or, if you hold your shares through a brokerage firm, bank or other nominee, on the voting instruction form provided by the broker, bank or nominee.

Q:     Who will solicit and pay the cost of soliciting proxies for the Special Meeting?

A:     The Company is soliciting proxies on behalf of its Board. The Company will pay the cost of soliciting proxies for the Special Meeting. The Company has engaged D.F. King to assist in the solicitation of proxies for the Special Meeting. The Company has agreed to pay D.F. King a fee of $25,000, plus disbursements, and will reimburse D.F. King for its reasonable out-of-pocket expenses and indemnify D.F. King and its affiliates against certain claims, liabilities, losses, damages and expenses. The Company will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing beneficial owners of shares of Company common stock for their expenses in forwarding soliciting materials to beneficial owners of the Company common stock and in obtaining voting instructions from those owners. Our directors, officers and employees may also solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies.

Q:     Who can help answer my questions?

A:     If you have questions about the proposals or if you need additional copies of this proxy statement/prospectus or the enclosed proxy card you should contact:

c/o Corvex Management LP
667 Madison Avenue
New York 10065
Attn: Eli Casdin
Email: Eli@casdincapital.com

You may also contact our proxy solicitor at:

D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, NY 10005

Stockholders Call (toll-free): (866) 864-7961
Banks and Brokers Call: (212) 269-5550
Email: CMII@dfking.com

To obtain timely delivery, our stockholders must request the materials no later than five business days prior to the Special Meeting.

You may also obtain additional information about us from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.”

If you intend to seek redemption of your public shares, you will need to send a letter demanding redemption and deliver your stock (either physically or electronically) to our Transfer Agent prior to the Special Meeting in accordance with the procedures detailed under the question “How do I exercise my redemption rights?” If you have questions regarding the certification of your position or delivery of your stock, please contact our Transfer Agent:

Continental Stock Transfer & Trust Company
1 State Street, 30th Floor
New York, New York 10004

Attention: Mark Zimkind
Email: mzimkind@continentalstock.com

24

Table of Contents

SUMMARY OF THE PROXY STATEMENT/PROSPECTUS

This summary highlights selected information contained in this proxy statement/prospectus and does not contain all of the information that may be important to you. You should carefully read this entire proxy statement/prospectus, including the Annexes and accompanying financial statements of the Company and SomaLogic, to fully understand the proposed Business Combination (as described below) before voting on the proposals to be considered at the Special Meeting (as described below). Please see the section entitled “Where You Can Find More Information” beginning on page 309 of this proxy statement/prospectus.

Unless otherwise specified, the ownership percentages with respect to the post-combination company following the Business Combination and PIPE Investment are based on aggregate Merger Consideration of 125,000,000 shares of CMLS II Class A Common Stock (assuming no cash elections will be made by SomaLogic stockholders) and assume 116,013,417 shares will be issued at Closing to current holders of issued and outstanding shares of SomaLogic stock, but does not include the portion of the Merger Consideration that will be allocated to shares underlying issued and outstanding options to acquire SomaLogic stock (totaling, in aggregate and after giving effect to the implied exchange ratio, 8,986,583 shares of CMLS II Class A common stock, calculated on a treasury stock basis) that may be exercised in the future. This calculation also excludes (x) the issuance of any shares following the completion of the Business Combination under the Incentive Plan or the ESPP, copies of which are attached to this proxy statement/prospectus as Annex C and Annex D, respectively, (y) the issuance of any Earn-Out Shares or (z) shares of CMLS II underlying warrants to purchase common stock of CMLS II that will remain outstanding following the Business Combination. In addition, the ownership percentages assume that no public shares are redeemed by the Company.

Parties to the Business Combination

The Company

The Company is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

The mailing address of the Company’s principal executive office is 667 Madison Avenue, New York, New York 10065.

Merger Sub

Merger Sub, a Delaware corporation, is a wholly-owned subsidiary of the Company, formed by the Company in Delaware, to consummate the Business Combination. In the Business Combination, Merger Sub will merge with and into SomaLogic, with SomaLogic surviving the Merger as a wholly-owned subsidiary of the Company.

The mailing address of Merger Sub’s principal executive office is 667 Madison Avenue, New York, New York 10065.

SomaLogic

SomaLogic is a commercial stage proteomics company and has historically served over 300 pharmaceutical and research customers and collaborators. The company’s pioneering technology platform is uniquely capable of becoming a universal proteomics solution. Proprietary aptamers, which are target specific oligonucleotides, facilitate both broad and precise protein measurements. The SomaScan® assay measures 7,000 protein target measurements in a single sample as of April 30, 2021, with high specificity, low variance and high reproducibility, enabling the possibility of faster, more precise drug discovery for researchers. The SomaSignal tests, one of the industry’s leading clinical proteomic diagnostic applications, which provide additional insights to a wide customer base, are a combination of artificial intelligence and machine learning powered bioinformatics algorithms operated in tandem with SomaLogic’s database of over 450,000 samples. Findings using this patented technology have been published by the company or collaborators in more than 250 scientific and clinical manuscripts with some of the leading KOLs.

The Business Combination Proposal

On March 28, 2021, the Company and Merger Sub entered into the Merger Agreement with SomaLogic. The SomaLogic stockholders have adopted and approved the Merger Agreement. CMLS II Class A common stock is currently listed on Nasdaq. If the Merger Agreement is approved by Company stockholders at the Special Meeting, Merger Sub will

25

Table of Contents

merge with and into SomaLogic, with SomaLogic surviving the merger as a wholly owned subsidiary of the Company. For more information about the transactions contemplated by the Merger Agreement, please see the section entitled “Proposal No. 1 — The Business Combination Proposal.” A composite copy of the Merger Agreement, incorporating the amendments into the text of the initial agreement, is attached to this proxy statement/prospectus as Annex A.

Merger Consideration to the SomaLogic Stockholders

Under the Merger Agreement, CMLS II has agreed to acquire all of the outstanding equity interests of SomaLogic for at least $1.25 billion in aggregate consideration consisting of 125,000,000 shares of CMLS II Class A common stock (assuming no cash elections will be made by SomaLogic stockholders) and up to an additional 5,000,000 shares of CMLS II Class A common stock pursuant to the Earn-Out Shares. Subject to the terms and conditions of the Merger Agreement, at the Effective Time, and as further described in this proxy statement/prospectus, each share of SomaLogic stock, other than Excluded Shares and Dissenting Shares (as defined in the Merger Agreement), that is issued and outstanding immediately prior to the Effective Time will be cancelled and automatically deemed for all purposes to represent the right to receive a portion of the total consideration, with each SomaLogic’s stockholder (as applicable) being entitled to receive:

(a)     if such stockholder has made a cash election as set forth and in accordance with the terms of the Merger Agreement, a portion of the specified aggregate amount of cash consideration payable under the terms of the Merger Agreement (such aggregate amount not to exceed $50,000,000) and pursuant to the terms of such stockholder’s cash election;

(b)     a number of shares of CMLS II Class A Common Stock equal to the quotient of: (i) (A) the product of (x) such stockholder’s total shares of SomaLogic stock (with the SomaLogic common stock and preferred stock (determined on an as-converted basis) included as a single class) multiplied by (y) the per share amount calculated in accordance with the Merger Agreement minus (B) the amount of cash payable to such stockholder pursuant to its cash election referenced in clause (a) above, if any, divided by (ii) $10.00; and

(c)     such stockholder’s earn-out pro rata share of any Earn-Out Shares to which such stockholder is entitled pursuant to the terms of the Merger Agreement.

Following the closing of the Business Combination, and as additional consideration for the Merger and the other transactions, if during the Earn-Out Period, the Triggering Event occurs, then we will deliver or cause to be delivered to each applicable SomaLogic stockholder in accordance with such stockholder’s respective earn-out pro rata share (other than holders of Dissenting Shares, as defined in the Merger Agreement), and Earn-Out Service Provider (in accordance with its respective earn-out pro rata share and, in the case of the Earn-Out Service Providers, in accordance with the terms of the applicable earn-out award agreement), the Earn-Out Shares. Such issuance shall be upon the terms and subject to the conditions set forth in the Merger Agreement and the other transaction agreements and, in the case of the Earn-Out Service Providers, subject to the additional requirements set forth in the Merger Agreement and the applicable earn-out award agreement.

After consideration of the factors identified and discussed in the section titled “The Business Combination Proposal — CMLS II Board of Directors’ Reasons for the Approval of the Business Combination,” the CMLS II Board concluded that the Business Combination met all of the requirements disclosed in the prospectus for CMLS II’s IPO, including that the aggregate fair market value of the proposed Business Combination was at least 80% of the net assets held in the Trust Account. For more information about the transactions contemplated by the Merger Agreement, please see the section entitled “The Business Combination Proposal.

For further details, please see the section entitled “The Business Combination Proposal — Merger Consideration.

Material U.S. Federal Income Tax Consequences of the Business Combination

It is the opinion of Reed Smith LLP that the Merger will qualify as a “reorganization” for U.S. federal income tax purposes within the meaning of Section 368(a) of the Code and/or as part of a transaction governed by Section 351 of the Code. Certain material U.S. federal income tax considerations that may be relevant to you in respect of the Business Combination are discussed in more detail in the section entitled “Certain Material U.S. Federal Income Tax Considerations.” The discussion of the U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and is not a complete analysis or description of all of the U.S. federal income tax considerations that are applicable to you in respect of the Business Combination, nor does it address any tax considerations arising under U.S. state or local or non-U.S. tax laws.

26

Table of Contents

TAX MATTERS ARE COMPLICATED, AND THE TAX CONSEQUENCES OF THE BUSINESS COMBINATION WILL DEPEND ON THE FACTS OF YOUR OWN SITUATION. YOU SHOULD CONSULT YOUR OWN TAX ADVISOR AS TO THE SPECIFIC TAX CONSEQUENCES OF THE BUSINESS COMBINATION TO YOU IN YOUR PARTICULAR CIRCUMSTANCES.

Related Agreements

This section describes the material provisions of the Related Agreements, but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of each of the Related Agreements. Forms of the Forfeiture Agreement, Stockholder Support Agreement, Sponsor Support Agreement and Subscription Agreement are attached hereto as Annexes G, H, I, and J, respectively. Stockholders and other interested parties are urged to read such Related Agreements in their entirety prior to voting on the proposals presented at the Special Meeting.

Amended and Restated Registration Rights Agreement

In connection with the closing of the Business Combination, the Company, the Sponsor and certain other parties thereto (collectively, the “rights holders”) expect to enter the Amended and Restated Registration Rights Agreement, which will amend and restate in its entirety the existing registration rights agreement, dated February 22, 2021, by and between CMLS II and the parties thereto. Pursuant to the terms of the Amended and Restated Registration Rights Agreement, CMLS II is to prepare and file with the SEC, no later than 30 days after the Closing Date, a shelf registration statement for an offering to be made on a continuous basis from time to time with respect to the resale of the registrable shares under the Amended and Restated Registration Rights Agreement. CMLS II is further required to use commercially reasonable efforts to cause such shelf registration statement to be declared effective as soon as possible after filing, but in no event later than the earlier of 60 days following the filing date thereof and five business days after the SEC notifies CMLS II that it will not review such registration statement, subject to extension in the event that the registration is subject comments from the SEC.

In addition, pursuant to the terms of the Amended and Restated Registration Rights Agreement and subject to certain requirements and customary conditions, including with regard to the number of demand rights that may be exercised, the rights holders may demand at any time or from time to time, that CMLS II file a registration statement on Form S-1 or Form S-3 to register certain shares of CMLS II Class A common stock held by such rights holders. The Amended and Restated Registration Rights Agreement will also provide the rights holders with “piggy-back” registration rights, subject to certain requirements and customary conditions. The Company will bear the expenses incurred in connection with the filing of any such registration statement.

Forfeiture Agreement

In connection with the execution of the Merger Agreement, the Company and the Sponsor entered into the Forfeiture Agreement whereby the Sponsor agreed to forfeit certain of its CMLS II Class B common stock. Under the Forfeiture Agreement, up to 33% of Sponsor’s shares are subject to forfeiture based on the extent of redemptions from the Trust Account, such that Sponsor shall forfeit the full 33% of such shares if there are redemptions for 100% of the Trust Account and no shares if there are 0% redemptions (with the portion of such 33% of Sponsor’s shares that are forfeited adjusting on a linear basis in between 100% and 0% redemptions from the Trust Account).

Stockholder Support Agreement

In connection with the execution of the Merger Agreement, CMLS II entered into the Stockholder Support Agreement with certain stockholders of SomaLogic, pursuant to which, among other things, such stockholders have agreed, respectively, to execute written consents with respect to their shares of SomaLogic stock held of record or thereafter acquired in favor of the Merger and related matters, in each case, on the terms and subject to the conditions set forth in the Stockholder Support Agreement.

Sponsor Support Agreement

In connection with the execution of the Merger Agreement, the Sponsor entered into the Sponsor Support Agreement with the Company and SomaLogic, pursuant to which, among other things, the Sponsor agreed to vote all shares of Company common stock beneficially owned by the Sponsor in favor of each of the proposals and any other matters necessary or reasonably requested by SomaLogic for consummation of the Merger and the other transactions contemplated by the Merger Agreement, and against any other competing business combination proposal.

27

Table of Contents

The Sponsor Support Agreement provides that the Sponsor will not redeem any shares of common stock in connection with the Merger.

The Sponsor also agreed, subject to certain exceptions, not to (a) transfer any of its CMLS II Class B common stock or private placement warrants, (b) enter into any swap or other arrangement that transfers to another the Sponsor’s CMLS II Class B common stock or private placement warrants, and (c) publicly announce any intention to effect any transaction specified by the foregoing until the earlier of (i) the Effective Time, (ii) such date and time as the Merger Agreement is terminated in accordance with its terms (the earlier of (i) and (ii), the “Expiration Time”), and (iii) the liquidation of the Company subsequent to the Closing.

The Sponsor Support Agreement provides for the terms of the Sponsor’s lock-up period with respect to its capital stock and warrants, the agreement also provides that no amendment may be made to the Inside Letter.

The Sponsor Support Agreement shall terminate and be of no further force or effect upon the earliest of: (i) the Expiration Time, (ii) the liquidation of the Company, and (iii) the written agreement of the Company, Sponsor and SomaLogic. Upon such termination of the Sponsor Support Agreement, all obligations of the parties under such agreement will terminate, without any liability or other obligation on the part of any party to any person in respect hereof or the transactions contemplated hereby, and no party shall have any claim against another (and no person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; provided, however, that the termination of the Sponsor Support Agreement shall not relieve any party hereto from liability arising in respect of any breach of this Sponsor Support Agreement prior to such termination.

Insider Letter

In connection with the underwriting agreement and the IPO of the Company, the Company, the Sponsor and each insider entered into the Insider Letter providing for a lock-up in relation to the Sponsor’s Class B common stock of the Company or any shares of Class A common stock of the Company until the earlier of (a) one year after the completion of the Company’s initial business combination and (b) subsequent to the business combination, (x) if the closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) for any 20 trading days within any 30-day trading day period commencing at least 150 days after the Company’s initial business combination, or (y) the date following the completion of the Company’s initial business combination on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Class A common stock for cash securities or other property. The Sponsor and each insider also agreed not to transfer any private placement warrants (or any share of Class A common stock issued or issuable upon the exercise of the private placement warrants), until 30 days after the completion of a business combination.

Subscription Agreements

In connection with the Business Combination, the Company entered into the Subscription Agreements with the PIPE Investors, pursuant to which, among other things, the Company agreed to issue and sell to the PIPE Investors, in private placements to close immediately prior to the Closing, an aggregate of 37,500,000 shares of common stock at $10.00 per share, for an aggregate purchase price of $375,000,000. The obligations to consummate the subscriptions are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Merger Agreement. The PIPE Investment will be consummated substantially concurrently with the Closing.

Lock-up Agreements

In connection with the execution of the Merger Agreement, SomaLogic agrees to use reasonable best efforts to obtain a Stockholder Lock-Up Agreement from each SomaLogic stockholder holding more than 1% of the outstanding capital stock of SomaLogic. Pursuant to such Stockholder Lock-Up Agreement, each stockholder agrees, from the Closing Date until the earliest of (a) the date that is 180 calendar days from the Closing Date, and (b) the date following the Closing Date on which the Company completes a liquidation, merger, stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Company capital stock for cash, securities or other property; not to (i) sell, offer to sell, contract or agree to sell, hypothecate pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, with respect to shares of CMLS II Class A common stock issued to such shareholder pursuant to the Merger Agreement

28

Table of Contents

(such shares of CMLS II Class A common stock, the “Lock-up Shares”), (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of the Lock-up Shares, in cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clause (i) or (ii). Notwithstanding the foregoing, the referred shareholder may take any of the actions specified in clauses (i), (ii) and (iii) above at any time after the first date on which the closing price of CMLS II Class A common stock has equaled or exceeded $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Closing Date.

Incentive Plan

Our Board approved the Incentive Plan on March 28, 2021, subject to stockholder approval of the Incentive Plan at the Special Meeting. The purpose of the Incentive Plan is to promote the long-term success of the post-combination company and the creation of stockholder value by encouraging service providers to focus on critical long-range corporate objectives, encouraging the attraction and retention of service providers, employees and directors with exceptional qualifications and linking service providers directly to stockholder interests through increased stock ownership. These incentives are provided through the grant of stock options, including incentive stock options, and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, and cash-based awards. For more information about the Incentive Plan, please see the section entitled “Proposal No. 3 — The Incentive Plan Proposal — Summary of the Incentive Plan.

Employee Stock Purchase Plan

Our Board approved the ESPP on March 28, 2021, subject to stockholder approval of the ESPP at the Special Meeting. The purpose of the ESPP Proposal is to provide eligible employees with an opportunity to increase their proprietary interest in the success of the post-combination company by purchasing common stock on favorable terms and to pay for such purchases through payroll deductions. We believe by providing eligible employees with an opportunity to increase their proprietary interest in the success of the post-combination company, the ESPP will motivate participants to offer their maximum effort to the post-combination company and help focus them on the creation of long-term value consistent with the interests of the post-combination company’s stockholders. For more information about the ESPP, please see the section entitled “Proposal No. 4 — The ESPP Proposal.”

Redemption Rights

Pursuant to our Current Charter, holders of public shares may elect to have their shares redeemed for cash at the applicable redemption price per share equal to the quotient obtained by dividing (i) the aggregate amount on deposit in the Trust Account as of two business days prior to the consummation of the Business Combination, including interest not previously released to the Company to pay its franchise and income taxes, by (ii) the total number of then-outstanding public shares; provided that the Company will not redeem any shares of common stock issued in the IPO to the extent that such redemption would result in the Company’s failure to have net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act) in excess of $5,000,001. As of March 31, 2021, the estimated per share redemption price would have been approximately $10.00.

If a holder exercises its redemption rights, then such holder will be exchanging its shares of our common stock for cash and will no longer own shares of the post-combination company. Such a holder will be entitled to receive cash for its public shares only if it properly demands redemption and delivers its shares (either physically or electronically) to our Transfer Agent in accordance with the procedures described herein. Please see the section entitled “Special Meeting of Company Stockholders — Redemption Rights” for the procedures to be followed if you wish to redeem your shares for cash. Any request for redemption may be withdrawn until the deadline for submitting redemption requests and thereafter, with our consent, until the Closing.

Impact of the Business Combination on the Company’s Public Float

It is anticipated that, upon completion of the Business Combination: (i) the Company’s public stockholders (other than the PIPE Investors) will retain an ownership interest, in the aggregate, of approximately 14.7% of the outstanding shares of the post-combination company; (ii) the PIPE Investors will own, in the aggregate, approximately 19.9% of the outstanding shares of the post-combination company (such that public stockholders, including PIPE Investors (including the affiliates of our Sponsor), will own, in the aggregate, approximately 34.6% of the outstanding shares of the post-combination company); (iii) our Initial Stockholders (including our Sponsor) will own, in the

29

Table of Contents

aggregate, approximately 3.7% of the outstanding shares of the post-combination company; and (iv) the former SomaLogic stockholders are expected to hold, in the aggregate, approximately 61.7% of the outstanding shares of the post-combination company. Refer to the pro forma post-combination company common stock issued and outstanding immediately after the Business Combination and PIPE Investment in the section entitled Unaudited Pro Forma Condensed Combined Financial Information”. The PIPE Investors have agreed to purchase 37,500,000 shares of common stock, in the aggregate, for $375,000,000 of gross proceeds.

The ownership percentages with respect to the post-combination and PIPE Investment are based on aggregate Merger Consideration of 125,000,000 shares of CMLS II Class A Common Stock (assuming no cash elections will be made by SomaLogic stockholders) and assume 116,013,417 shares will be issued at Closing to current holders of issued and outstanding shares of SomaLogic stock, but does not include the portion of the Merger Consideration that will be allocated to shares underlying issued and outstanding options to acquire SomaLogic stock (totaling, in aggregate and after giving effect to the implied exchange ratio, 8,986,583 shares of CMLS II Class A common stock, calculated on a treasury stock basis) that may be exercised in the future. This calculation also excludes (x) the issuance of any shares following the completion of the Business Combination under the Incentive Plan or the ESPP, copies of which are attached to this proxy statement/prospectus as Annex C and Annex D, respectively, (y) the issuance of any Earn-Out Shares or (z) shares of CMLS II underlying warrants to purchase common stock of CMLS II that will remain outstanding following the Business Combination. In addition, the ownership percentages assume that no public shares are redeemed by the Company. If the actual facts are different than these assumptions, which they are likely to be, the ownership percentages in the post-combination company will be different from the above stated ownership percentages. For more information, please see the sections entitled “Summary of the Proxy Statement/Prospectus — Impact of the Business Combination on the Company’s Public Float,” “Unaudited Pro Forma Condensed Combined Financial Information,” “Proposal No. 3 — The Incentive Plan Proposal” and “Proposal No. 4 — The ESPP Proposal.”

The following table illustrates varying ownership levels in the Company, assuming no redemptions by the Company’s public stockholders and the maximum redemptions by the Company’s stockholders:

 

# of shares assuming no
redemptions

 

% assuming no
redemptions

 

# of shares
assuming
maximum
redemptions

 

% assuming
maximum
redemptions

Public stockholders

 

27,600,000

 

14.7%

 

 

0.0%

PIPE Investors(1)

 

37,500,000

 

19.9%

 

37,500,000

 

23.7%

Initial Stockholders

 

6,900,000

 

3.7%

 

4,623,000

 

2.9%

Former SomaLogic stockholders(2)

 

116,013,417

 

61.7%

 

116,013,417

 

73.4%

   

188,013,417

 

100%

 

158,136,417

 

100%

____________

(1)      The PIPE Investors includes 5,450,000 shares held by affiliates of our Sponsor.

(2)      Please see the section entitled “Unaudited Pro Forma Condensed Combined Financial Information”.

Other Proposals

In addition, the stockholders of the Company will be asked to vote on:

•        a proposal to approve, for purposes of complying with applicable Nasdaq Listing Rules, the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Business Combination and the PIPE Investment (Proposal No. 2);

•        a proposal to approve and adopt the Incentive Plan, a copy of which is attached to this proxy statement/prospectus as Annex C, including the authorization of the initial share reserve under the Incentive Plan (Proposal No. 3);

•        a proposal to approve and adopt the ESPP, a copy of which is attached to this proxy statement/prospectus as Annex D, including the authorization of the initial share reserve under the ESPP (Proposal No. 4);

•        a proposal to adopt the A&R Certificate of Incorporation, a copy of which is attached to this proxy statement/prospectus as Annex E (Proposal No. 5); and

30

Table of Contents

•        a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal (Proposal No. 6).

Please see the sections entitled “Proposal No. 2 — The Nasdaq Stock Issuance Proposal,” “Proposal No. 3 — The Incentive Plan Proposal,” “Proposal No. 4 — The ESPP Proposal,” “Proposal No. 5 — The Charter Amendment Proposal,” and “Proposal No. 6 — The Adjournment Proposal” for more information.

Date and Time of Special Meeting

The Special Meeting will be held on [day], [date] at [time] Eastern time at [virtual meeting link], or at such other date, time and place to which such meeting may be adjourned or postponed, to consider and vote upon the proposals. The Special Meeting will be conducted exclusively via live webcast and so stockholders will not be able to attend the meeting in person. Stockholders may attend the Special Meeting online and vote at the Special Meeting by visiting [virtual meeting link] and entering your 12-digit control number, which is either included on the proxy card you received or obtained through Continental Stock Transfer & Trust Company.

Registering for the Special Meeting

Any stockholder wishing to attend the virtual meeting should register for the meeting by [date] at [virtual meeting link]. To register for the Special Meeting, please follow these instructions as applicable to the nature of your ownership of our common stock:

•        If your shares are registered in your name with Continental Stock Transfer & Trust Company and you wish to attend the online-only Special Meeting, go to [virtual meeting link], enter the 12-digit control number included on your proxy card or notice of the meeting and click on the “Click here to preregister for the online meeting” link at the top of the page. Just prior to the start of the meeting you will need to log back into the meeting site using your control number. Pre-registration is recommended but is not required in order to attend.

•        Beneficial stockholders (those holding shares through a stock brokerage account or by a bank or other holder of record) who wish to attend the virtual meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and e-mail a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Beneficial stockholders who e-mail a valid legal proxy will be issued a 12-digit meeting control number that will allow them to register to attend and participate in the Special Meeting. After contacting Continental Stock Transfer & Trust Company, a beneficial holder will receive an e-mail prior to the meeting with a link and instructions for entering the virtual meeting. Beneficial stockholders should contact Continental Stock Transfer & Trust Company at least five business days prior to the meeting date in order to ensure access.

Voting Power; Record Date

Only Company stockholders of record at the close of business on [•], 2021, the record date for the Special Meeting, will be entitled to vote at the Special Meeting. You are entitled to one vote for each share of Company common stock that you owned as of the close of business on the record date. If your shares are held in “street name” or are in a margin or similar account, you should contact your broker, bank or other nominee to ensure that votes related to the shares you beneficially own are properly counted. On the record date, there were 34,500,000 shares of Company common stock outstanding and entitled to vote, of which 27,600,000 are public shares and 6,900,000 are Founder Shares held by our Initial Stockholders.

Accounting Treatment

The Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, the Company will be treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of SomaLogic issuing stock for the net assets of the Company, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded.

31

Table of Contents

Appraisal Rights

Appraisal rights are not available to our stockholders in connection with the Business Combination.

Proxy Solicitation

The Company is soliciting proxies on behalf of its Board. Proxies may be solicited by mail. The Company has engaged D.F. King to assist in the solicitation of proxies.

If a stockholder grants a proxy, it may still vote its shares at the Special Meeting if it revokes its proxy before the Special Meeting. A stockholder may also change its vote by submitting a later-dated proxy, as described in the section entitled “Special Meeting of Company Stockholders — Revoking Your Proxy.”

Interests of Certain Persons in the Business Combination

In considering the recommendation of our Board to vote in favor of the Business Combination, stockholders should be aware that aside from their interests as stockholders, our Sponsor and certain members of our Board and officers have interests in the Business Combination that are different from, or in addition to, those of other stockholders generally. Our Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination, and in recommending to stockholders that they approve the Business Combination. Stockholders should take these interests into account in deciding whether to approve the Business Combination.

These interests include, among other things:

•        the fact that our Initial Stockholders have agreed not to redeem any of the Founder Shares in connection with a stockholder vote to approve the Business Combination;

•        the fact that our Initial Stockholders will retain up to 6,900,000 Founder Shares upon the Closing;

•        the fact that our Initial Stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if we fail to complete an initial business combination by the applicable deadline;

•        if the Trust Account is liquidated, including in the event we are unable to complete an initial business combination within the required time period, our Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on the liquidation date, by the claims of prospective target businesses with which we have entered into an acquisition agreement or claims of any third party (other than our independent public accountants) for services rendered or products sold to us, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the Trust Account;

•        the continued indemnification of our existing directors and officers and the continuation of our directors’ and officers’ liability insurance after the Business Combination;

•        the fact that Eli Casdin, Kevin Conroy, Troy Cox and Stephen Quake will continue as board members of the post-combination company, and shall be entitled to receive compensation for serving on the board of directors of the post-combination company;

•        the fact that certain entities with which Mr. Casdin is affiliated collectively own approximately 8.6% of SomaLogic’s outstanding stock on an as-converted basis, and Mr. Casdin serves on the board of directors of SomaLogic;

•        the fact that our Sponsor, officers and directors will lose their entire investment in us and will not be reimbursed for any out-of-pocket expenses if an initial business combination is not consummated by the applicable deadline;

•        the fact that the Initial Stockholders (including entities controlled by the Company’s officers and directors) have made an aggregate average investment per share of CMLS II Class B common stock of less than $0.01 as of the consummation of the Company’s IPO, and as a result of the significantly lower investment

32

Table of Contents

per share of the Initial Stockholders as compared with the investment per share of the Initial Stockholders, a transaction which results in an increase in the value of the investment of the Initial Stockholders may result in a decrease in the value of the investment of the Company’s public stockholders;

•        the fact that simultaneously with the closing of the IPO, the Company completed the private sale of an aggregate of 5,013,333 warrants at a purchase price of $1.50 per private placement warrant, to the Sponsor and certain of the Company’s directors (and/or entities controlled by them) generating gross proceeds to the Company of $7,520,000, and if a business combination is not consummated by the applicable deadline, the proceeds from the sale of the private placement warrants will be used to fund the redemption of public shares (subject to the requirements of applicable law), and the private placement warrants will be worthless;

•        the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate;

•        the fact that given the differential in purchase price that our Sponsor paid for the Founder Shares as compared to the price of the units sold in the IPO and the substantial number of shares of post-combination company common stock that our Sponsor will receive upon conversion of the Founder Shares in connection with the Business Combination, our Sponsor and its affiliates may realize a positive on such investments even if other CMLS II stockholders experience a negative rate of return following the Business Combination; and

•        that affiliates of the Sponsor, Casdin Capital LLC and Corvex Management L.P. and Dr. Quake and Mr. Cox, have entered into Subscription Agreements with the Company, pursuant to which such affiliates have committed to purchase 2,500,000; 2,500,000; 400,000 and 50,000 shares of common stock in the PIPE Investment, respectively, for an aggregate commitment of approximately $25,000,000; $25,000,000; $4,000,000; $500,000, respectively.

Reasons for the Approval of the Business Combination

We were formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We sought to do this by utilizing the networks and industry experience of both our Sponsor and our Board to identify, acquire and operate one or more businesses within or outside of the United States, although we were not limited to a particular industry or sector, we focused on the life sciences sector.

In particular, our Board considered the following positive factors, although not weighted or in any order of significance:

•        Opportunities Arising from SomaLogic’s Business and Growth Model.    Our Board considered SomaLogic’s focus on the opportunities arising from its leadership in proteomics, a strong revenue base, and the goal of developing a universal proteomics platform to enable biomedical discovery, advance translational research and transform clinical diagnostics. Our Board believes the additional cash available to SomaLogic from the transaction will accelerate its business plan.

•        Committed and Capable Management Team.    Our Board considered that SomaLogic has an experienced and professional management team. Roy Smythe, SomaLogic’s Chief Executive Officer, held senior management positions throughout the industry including Royal Philips to Valence Health and AVIA.

•        Fairness Opinion. The financial analysis reviewed by Houlihan Lokey Capital, Inc. (“Houlihan Lokey”) with the Board as well as the oral opinion of Houlihan Lokey rendered to the Board on March 28, 2021 (which was subsequently confirmed in writing by delivery of Houlihan Lokey’s written opinion addressed to the Board dated March 28, 2021), as to the fairness, from a financial point of view, to CMLS II of the Closing Merger Consideration (defined below) to be issued and paid by CMLS II in the Merger pursuant to the Merger Agreement. The Merger Consideration, excluding any Earn-Out Shares to which a stockholder is entitled pursuant to the terms of the Merger Agreement is referred to herein as the “Closing Merger Consideration.”

•        Potential for Key Industry Partnerships.    The SomaLogic Board and management team includes individuals with relationships across the industry allowing SomaLogic to strategically create synergistic collaborations and partnerships with other companies and healthcare systems in the industry.

33

Table of Contents

•        Potential to Grow Through Both Organic and Inorganic Opportunities.    Our Board considered that SomaLogic has the potential to grow organically with its commercial sales and business development efforts focused on the life sciences and diagnostic healthcare markets. In addition, SomaLogic is in an industry with opportunities and rationale for inorganic growth through acquisitions of complementary businesses in addition to organic growth. The ability to take advantage of these opportunities is expected to be facilitated by the additional cash being made available to SomaLogic as a result of the Business Combination.

•        Benefit of Adding Members of the CMLS II Board to the SomaLogic Board.    Our Board considered that the addition of members of the CMLS II Board to the SomaLogic Board as part of the Business Combination provides additional Board members experienced in the life sciences industry and public companies.

•        Familiarity of Management with SomaLogic.    Certain members of management of CMLS II associated with Casdin Capital LLC have historical familiarity with SomaLogic because Casdin Capital has been an active investor in the life sciences industry for over 10 years. Eli Casdin, who has served as a director of SomaLogic since December 2020 (upon being designated by the holders of SomaLogic’s Series A preferred stock pursuant to the terms of the Series A Financing described in this section), currently serves as the Chief Executive Officer of CMLS II. Because of this familiarity, Casdin Capital’s due diligence of SomaLogic in connection with its previous investment in SomaLogic and Mr. Casdin’s position at SomaLogic, Mr. Casdin was familiar with the information about SomaLogic’s business and growth opportunities that was presented to our Board.

•        Other Alternatives.    Our Board believed that the proposed Business Combination represents an excellent opportunity for CMLS II and its stockholders based upon its view of the growth prospects and risks associated with SomaLogic and its business, and at the time it approved the transaction had not identified another target that it determined would represent a preferred transaction opportunity.

•        Terms of the Merger Agreement.    Our Board considered the terms and conditions of the Merger Agreement and the transactions contemplated thereby, including the Business Combination. In particular our Board noted the limited number of conditions to closing of the Business Combination.

•        PIPE Equity Commitment.    A group of institutional and accredited investors, including certain existing SomaLogic stockholders, and our Sponsor have committed $375,000,000 in PIPE subscriptions, $320,500,000 of which are from investors not associated with our Sponsor. This was viewed as support from institutional investors for the opportunities represented by the transaction, and provides for additional capital for the execution by SomaLogic of its business plan after the transaction is completed.

•        Sellers’ Retained Interest.    SomaLogic’s stockholders’ retention of a large stake in the business combination shows ongoing commitment and support for the post-combination company.

For a complete list of the factors considered by the CMLS II Board, please see the section entitled “The Business Combination Proposal — CMLS II Board of Directors’ Reasons for the Approval of the Business Combination.

Conditions to Closing the Business Combination

Conditions to Each Party’s Obligations

The respective obligations of the Company and SomaLogic to complete the Business Combination are subject to the satisfaction of the following conditions:

•        the approval of the Merger Agreement and the transactions contemplated by the Merger Agreement by the requisite vote of the Company stockholders;

•        the Company must have $5,000,001 of net tangible assets, as more fully described in “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Conditions to the Merger” on page 141;

•        the applicable waiting period(s) under the HSR Act and, if required, any other applicable antitrust law in respect of the transactions contemplated by the Merger Agreement must have expired or been terminated and the parties to the Merger Agreement have received or been deemed to have received all other necessary pre-closing authorizations, consents, clearances, waivers and approvals of all governmental entities in connection with the execution, delivery and performance of the Merger Agreement and the related transactions set forth on the disclosure schedules; and

34

Table of Contents

•        there must be no legal requirement prohibiting, enjoining or making illegal the consummation of the transactions contemplated by the Merger Agreement and no restraining order prohibiting, enjoining or making illegal the consummation of such transactions may be in effect, as more fully described in “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Conditions to the Merger” on page 141.

Conditions to Obligations of the Company

The obligation of the Company to complete the Merger is also subject to the satisfaction, or waiver by the Company, of the following conditions:

•        the representations and warranties of SomaLogic related to organization, qualification, subsidiaries, due authorization, brokers and third party expenses, and absence of certain business practices must be true and correct in all material respects (without giving effect to any limitation as to “materiality” or “material adverse effect” or any similar limitation contain herein) on and as of the date of the Merger Agreement and on as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date);

•        the representations and warranties of SomaLogic set forth in the capitalization representation must be true and correct in all respects on and as of the date of the Agreement and on as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date), except for any de minimis inaccuracies;

•        all other representations and warranties of SomaLogic set forth in the Merger Agreement must be true and correct (without giving effect to any limitation as to “materiality” or “material adverse effect” or any similar limitation contained herein) on and as of the date of the Merger Agreement and on as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date), except where the failure of such representations and warranties of SomaLogic to be so true and correct, individually or in the aggregate, has not had and is not reasonably likely to have a material adverse effect;

•        SomaLogic must have performed or complied with all agreements and covenants required by the Merger Agreement to be performed or complied with by it at or prior to the Closing Date, in each case in all material respects;

•        SomaLogic must have delivered to the Company a certificate signed by an executive officer of SomaLogic certifying that the two preceding conditions have been satisfied;

•        the SomaLogic Stockholder Approval shall have been obtained;

•        no material adverse effect may have occurred since the date of the Merger Agreement that is continuing; and

•        SomaLogic must have delivered, or caused to have been delivered, or must stand ready to deliver all of the certificates, instruments, contracts and other documents specified to be delivered by it hereunder, including copies of the documents to be delivered by the company pursuant to the Merger Agreement, duly executed by the applicable signatory or signatories specified therein, if any.

Conditions to Obligations of SomaLogic

The obligation of SomaLogic to complete the Merger is also subject to the satisfaction or waiver by SomaLogic of the following conditions:

•        the representations and warranties of the Company related to organization, subsidiaries, authority in relation to the Merger Agreement and business activities and liabilities must be true and correct in all material respects (without giving effect to any limitation as to “materiality” or “material adverse effect” or any similar limitation contain herein) on and as of the date of the Merger Agreement and on and as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date);

35

Table of Contents

•        the representations and warranties of the Company set forth in the capitalization representation must be true and correct in all respects on and as of the date of the Merger Agreement and on as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date), except for any de minimis inaccuracies;

•        all other representations and warranties of the Company set forth in the Merger Agreement must be true and correct (without giving effect to any limitation as to “materiality” or “material adverse effect” or any similar limitation contained herein) on and as of the date of the Merger Agreement and on as of the Closing Date as though made on and as of the Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty must be true and correct as of such earlier date), except where the failure of such representations and warranties of the Company to be so true and correct, individually or in the aggregate, has not had and is not reasonably likely to have a material adverse effect;

•        the Company and Merger Sub must have performed or complied with all agreements and covenants required by the Merger Agreement to be performed or complied with by them on or prior to the Closing Date, in each case in all material respects;

•        the Company must have delivered to SomaLogic a certificate, signed by an executive officer of the Company and dated as of the Closing Date, certifying that the two preceding conditions have been satisfied;

•        the Company must have delivered or must stand ready to deliver all of the certificates, instruments, contracts and other documents specified to be delivered by it hereunder, including copies of the documents to be delivered by the Company pursuant to the Merger Agreement, duly executed by the Company and Merger Sub, as applicable;

•        the Company must have made appropriate arrangements to have the Trust Account, less amounts paid and to be paid pursuant the Merger Agreement, available to the Company for payment of the cash payment amount to be paid at Closing, and the Company and SomaLogic transaction costs at the Closing;

•        the funds contained in the Trust Account, together with the Subscription Agreements to be received substantially concurrently with the Closing, must equal or exceed $250,000,000, following payment of the aggregate amount of cash proceeds that will be required to satisfy any exercise of the redemptions by the Company stockholders;

•        the shares of Company common stock to be issued in connection with the Merger must have been approved for listing on the Nasdaq; and

•        no material adverse effect must have occurred since the date of the Merger Agreement and be continuing.

Termination

The Merger Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including, among others, the following:

•        by mutual written agreement of CMLS II and SomaLogic at any time;

•        by either CMLS II or SomaLogic (i) if the Transactions shall not have been consummated by the Outside Date; provided, however, that the right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of or resulted in the failure of the transactions to occur on or before such date and such action or failure to act constitutes a breach of the Merger Agreement; (ii) if a governmental entity has issued an order or taken any other action, in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions, including the Merger, which order or other action is final and non-appealable; or (iii) at the Special Meeting (including any adjournments thereof), the Company’s stockholder matters are not duly adopted by stockholders of CMLS II by the requisite vote under the DGCL and our Current Charter;

•        by SomaLogic, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement on the part of CMLS II or Merger Sub, or if any representation or warranty of CMLS II or Merger

36

Table of Contents

Sub has become untrue, in either case such that the conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become untrue; provided, that if such breach by CMLS II or Merger Sub is curable by CMLS II or Merger Sub prior to the Closing, then SomaLogic must first provide written notice of such breach and may not terminate the Merger Agreement in accordance with Section 9.1(d) thereof until the earlier of: (i) 30 days after delivery of written notice from SomaLogic to CMLS II of such breach; and (ii) the Outside Date; provided, further, that each of CMLS II and Merger Sub continues to exercise commercially reasonable efforts to cure such breach (it being understood that SomaLogic may not terminate the Merger Agreement pursuant to Section 9.1(d) thereof if: (A) it has materially breached the Merger Agreement and such breach has not been cured; or (B) if such breach by CMLS II or Merger Sub is cured during such 30-day period);

•        by CMLS II, upon a breach of any representation, warranty, covenant or agreement set forth in the Merger Agreement on the part of SomaLogic or if any representation or warranty of SomaLogic has become untrue, in either case such that the conditions set forth in the Merger Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become untrue; provided, that if such breach is curable by SomaLogic prior to the Closing, then CMLS II must first provide written notice of such breach and may not terminate the Merger Agreement under Section 9.1(e) thereof until the earlier of: (i) 30 days after delivery of written notice from the Company to the SomaLogic of such breach; and (ii) the Outside Date; provided, further, that SomaLogic continues to exercise commercially reasonable efforts to cure such breach (it being understood that CMLS II may not terminate the Merger Agreement pursuant to Section 9.1(e) thereof if: (A) it has materially breached this Agreement and such breach has not been cured; or (B) if such breach by SomaLogic is cured during such 30-day period); or

•        by SomaLogic, if the redemptions by the Company stockholders results in the Aggregate Transaction Proceeds Condition becoming incapable of being satisfied at the Closing.

Regulatory Matters

Under the HSR Act and the rules that have been promulgated thereunder by the U.S. Federal Trade Commission (“FTC”), certain transactions may not be consummated unless information has been furnished to the Antitrust Division of the Department of Justice (“Antitrust Division”) and the FTC and certain waiting period requirements have been satisfied. The Business Combination is subject to these requirements and may not be completed until the expiration of a 30-day waiting period following the filing of the required Notification and Report Forms with the Antitrust Division and the FTC or until early termination is granted. If the FTC or the Antitrust Division makes a request for additional information or documentary material related to the Business Combination (a “Second Request”), the waiting period with respect to the Business Combination will be extended for an additional period of 30 calendar days, which will begin on the date on which the Company and SomaLogic each certify compliance with the Second Request. Complying with a Second Request can take a significant period of time. On April 9, 2021, the Company and SomaLogic filed the required forms under the HSR Act with the Antitrust Division and the FTC. The waiting period under the HSR Act with respect to the Business Combination expired on May 10, 2021.

At any time before or after consummation of the Business Combination, notwithstanding any termination of the waiting period under the HSR Act, the applicable competition authorities could take such action under applicable antitrust laws as each deems necessary or desirable in the public interest, including seeking to enjoin the consummation of the Business Combination. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. We cannot assure you that the Antitrust Division, the FTC, any state attorney general, or any other government authority will not attempt to challenge the Business Combination on antitrust grounds, and, if such a challenge is made, we cannot assure you as to its result. Neither the Company nor SomaLogic is aware of any material regulatory approvals or actions that are required for completion of the Business Combination other than the expiration or early termination of the waiting period under the HSR Act. It is presently contemplated that if any such additional regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained.

Quorum and Required Vote for Proposals for the Special Meeting

A quorum of Company stockholders is necessary to hold a valid meeting. A quorum will be present at the Special Meeting if a majority of the common stock outstanding on the record date and entitled to vote at the Special Meeting is represented in person or by proxy. Abstentions will count as present for the purposes of establishing a quorum.

37

Table of Contents

The approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal, the Adjournment Proposal requires the affirmative vote of a majority of the votes cast by holders of our common stock represented in person or by proxy and entitled to vote at the Special Meeting.

The approval of the Charter Amendment Proposal requires the affirmative vote of the holders of at least a majority of the outstanding shares of our common stock.

A failure to vote or an abstention will have no effect on the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal. An abstention or broker non-vote will have the same effect as a vote against the Charter Amendment Proposal.

The proposals in this proxy statement/prospectus (other than the Adjournment Proposal) are conditioned on the approval of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal and the ESPP Proposal. The approval of the Charter Amendment Proposal is not a condition to the other proposals in this proxy statement/prospectus. In case the Charter Amendment Proposal is not approved, the Current Charter will continue to be the certificate of incorporation of the post-combination company.

It is important for you to note that in the event that the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal or the ESPP Proposal do not receive the requisite vote for approval, we will not consummate the Business Combination. If we do not consummate the Business Combination and fail to complete an initial business combination by the applicable deadline, we will be required to dissolve and liquidate our Trust Account by returning the then remaining funds in such account to our public stockholders.

Recommendation to Company Stockholders

Our Board believes that each of the Business Combination Proposal, the Nasdaq Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal, the Charter Amendment Proposal and the Adjournment Proposal to be presented at the Special Meeting is in the best interests of the Company and our stockholders and recommends that its stockholders vote “FOR” each of the proposals.

When you consider the recommendation of our Board in favor of approval of the Business Combination Proposal, you should keep in mind that our Sponsor and certain members of our Board and officers have interests in the Business Combination that are different from or in addition to (or which may conflict with) your interests as a stockholder. Stockholders should take these interests into account in deciding whether to approve the proposals presented at the Special Meeting, including the Business Combination Proposal. Please see the section entitled “Special Meeting of Company Stockholders — Recommendation to Company Stockholders.”

Risk Factors Summary

In evaluating the proposals to be presented at the Special Meeting, a CMLS II stockholder should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section titled “Risk Factors.

Some of the risks related to SomaLogic’s business and industry and CMLS II’s business are summarized below. References in the summary below to “SomaLogic” generally refer to SomaLogic, Inc. in the present tense or the post-combination company from and after the Business Combination.

•        SomaLogic is an early-stage life sciences technology company that has incurred losses since inception, and SomaLogic expects to make significant investments in its continued research and development of new services and products, which may not be successful.

•        Seasonality may cause fluctuations in SomaLogic’s revenue and results of operations. SomaLogic’s operating results have in the past fluctuated significantly and may continue to fluctuate significantly in the future, which makes its future results difficult to predict and could cause its operating results to fall below expectations or any guidance we may provide.

•        SomaLogic’s current and future services and products may never achieve significant commercial market acceptance.

38

Table of Contents

•        SomaLogic’s business will depend significantly on research and development spending by pharmaceuticals, biotechnology, and academic, governmental and other research institutions, and any reduction in spending could limit demand for SomaLogic’s services and adversely affect the business, results of operations, financial condition and prospects.

•        The life sciences industry is subject to rapid change, which could make SomaLogic’s proteomics platform and related services and products that we develop obsolete. SomaLogic’s long term results depend upon its ability to improve existing services and products, and our ability to introduce and market new services and products successfully.

•        The majority of SomaLogic’s operations and laboratory processes are currently conducted at a single location in Boulder, Colorado and any disruption at SomaLogic’s facility could negatively impact its operations and increase expenses.

•        Unfavorable U.S. or global economic conditions as a result of the COVID-19 pandemic, or otherwise, could adversely affect SomaLogic’s ability to raise capital, results of operations and financial conditions.

•        Cybersecurity risks that could result in damage to SomaLogic’s data integrity and subject it to fines or lawsuits under data privacy laws.

•        SomaLogic depends on its key personnel and other highly qualified personnel, and if it’s unable to recruit, train and retain its personnel, SomaLogic may not achieve its goals.

•        If SomaLogic fails to protect its intellectual property effectively, its business would be harmed. SomaLogic’s inability to effectively protect its proprietary technologies, including the confidentiality of trade secrets, could harm its competitive position.

•        SomaLogic is in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce its revenue, adversely affect SomaLogic’s results of operations and financial condition and harm its business.

•        SomaLogic’s products could become subject to government regulation as medical devices by the FDA and other regulatory agencies, which could adversely impact its ability to market and sell its products and harm its business.

•        SomaLogic could be adversely affected by alleged violations of the Federal Trade Commission Act or other truth-in-advertising and consumer protection laws.

•        The requirements of being a public company may strain SomaLogic’s resources, result in litigation and divert management’s attention.

•        Sponsor, certain members of the Board and officers of CMLS II have interests in the Business Combination that are different from or are in addition to other stockholders in recommending that stockholders vote in favor of approval of the Business Combination Proposal and approval of the other proposals described in this proxy statement/prospectus.

•        The public stockholders of CMLS II will experience dilution as a consequence of, among other transactions, the issuance of common stock as consideration in the Business Combination and the PIPE Investment. Having a minority share position may reduce the influence that current stockholders of CMLS II have on the management of the post-combination company.

•        The exercise of discretion by the CMLS II directors and officers in agreeing to changes to the terms of or waivers of closing conditions in the Merger Agreement may result in a conflict of interest when determining whether such changes to the terms of the Merger Agreement or waivers of conditions are appropriate and in the best interests of the stockholders of CMLS II.

•        Changes in laws, regulations or rules, or a failure to comply with any laws, regulations or rules, may adversely affect CMLS II’s business, investments and results of operations.

•        There is no guarantee that a stockholder’s decision whether to redeem its shares for a pro rata portion of the Trust Account will put the stockholder in a better future economic position.

39

Table of Contents

SELECTED HISTORICAL FINANCIAL INFORMATION OF THE COMPANY

The following table contains summary historical financial data for the Company as of March 31, 2021 and as of December 31, 2020. Only balance sheet data is presented as of December 31, 2020 as we did not have any significant operations as of and for the period ended on such date. The selected historical financial information as of December 31, 2020 has been derived from the audited balance sheet of the Company, and the selected historical financial information as of March 31, 2021 has been derived from the unaudited condensed financial statements of the Company, both of which are included elsewhere in this proxy statement/prospectus. The information below is only a summary and should be read in conjunction with the sections entitled “The Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Information About the Company” and our financial statements, and the notes and schedules related thereto, which are included elsewhere in this proxy statement/prospectus.

 

For the Three Months Ended March 31,
2021

Statement of Operations Data:

   

Loss from operations

 

$

(57,619

)

Other income:

 

 

 

 

Interest earned on cash and marketable securities held in Trust Account

 

 

2,571

 

Offering costs allocated to warrants

 

 

(504,743

)

Change in fair value of warrant liability

 

 

(25,851,465

)

Total other income

 

 

(26,353,637

)

Net loss

 

$

(26,411,256

)

Weighted average shares outstanding of Class A common stock, basic and diluted

 

 

27,600,000

 

Basic and diluted net loss per share, Class A

 

$

 

Weighted average shares outstanding of Class B common stock, basic and diluted

 

 

6,294,231

 

Basic and diluted net loss per share, Class B

 

$

(4.20

)

   

 

 

 

Statement of Cash Flows Data:

 

 

 

 

Net cash used in operating activities

 

$

(239,698

)

Net cash used in investing activities

 

 

(276,000,000

)

Net cash provided by financing activities

 

 

277,831,753

 

 

As of
March 31,
2021

 

As of
December 31,
2020

Balance Sheet Data:

       

Working capital (deficiency)

 

$

1,470,996

 

$

(48,340

)

Total assets

 

 

277,775,567

 

 

72,202

 

Total liabilities

 

 

52,220,665

 

 

48,340

 

Stockholders’ equity

 

 

5,000,002

 

 

23,862

 

40

Table of Contents

SELECTED HISTORICAL FINANCIAL INFORMATION OF SOMALOGIC

The following table sets forth summary historical financial information of SomaLogic for the periods and as of the dates indicated. The summary historical financial information of SomaLogic as of and for the years ended December 31, 2020, and 2019 was derived from the audited consolidated financial statements of SomaLogic included elsewhere in this proxy statement/prospectus. The selected historical financial information of SomaLogic as of and for the three months ended March 31, 2021 and 2020 was derived from the unaudited condensed consolidated financial statements of SomaLogic included elsewhere in this proxy statement/prospectus.

The following summary historical financial information should be read together with SomaLogic’s consolidated financial statements and accompanying notes and “SomaLogic’s Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this proxy statement/prospectus. The summary historical financial information in this section is not intended to replace SomaLogic’s financial statements and the related notes thereto. SomaLogic’s historical results are not necessarily indicative of the results that may be expected in the future.

Selected Historical Balance Sheet Information

(dollars in thousands)

 

As of March 31,

 

As of December 31,

2021

 

2020

 

2019

Cash and cash equivalents

 

$

85,453

 

 

$

164,944

 

 

$

14,060

Working capital(1)

 

 

204,830

 

 

 

214,178

 

 

 

50,863

Total assets

 

 

238,083

 

 

 

242,290

 

 

 

71,262

Total liabilities

 

 

57,580

 

 

 

56,373

 

 

 

50,842

Total stockholders’ equity (deficit)

 

 

(21,613

)

 

 

(16,199

)

 

 

20,420

____________

(1)      SomaLogic defines working capital as current assets less current liabilities.

Selected Historical Income Statement Information

(dollars in thousands, except for share and per share amounts)

 

Three Months Ended March 31,

 

Year Ended December 31,

2021

 

2020

 

2020

 

2019

Total revenue

 

$

18,860

 

 

$

6,273

 

 

$

55,889

 

 

$

32,187

 

Total operating expenses

 

 

27,172

 

 

 

22,336

 

 

 

90,245

 

 

 

84,500

 

Loss from operations

 

 

(8,312

)

 

 

(16,063

)

 

 

(34,356

)

 

 

(52,313

)

Total other expense

 

 

(1,172

)

 

 

(1,516

)

 

 

(18,659

)

 

 

(4,689

)

Net loss

 

$

(9,484

)

 

$

(17,579

)

 

$

(53,015

)

 

$

(57,002

)

Net loss per share, basic and diluted

 

$

(0.13

)

 

$

(0.24

)

 

$

(0.73

)

 

$

(0.79

)

Weighted-average shares used to compute net loss per share, basic and diluted

 

 

73,617,247

 

 

 

72,554,477

 

 

 

72,833,736

 

 

 

72,365,489

 

Selected Historical Statement of Cash Flows Information

 

Three Months Ended March 31,

 

Year Ended December 31,

(dollars in thousands)

 

2021

 

2020

 

2020

 

2019

Net cash provided by (used in):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(3,891

)

 

$

(11,210

)

 

$

(28,338

)

 

$

(50,536

)

Investing activities

 

 

(75,682

)

 

 

19,703

 

 

 

(9,535

)

 

 

30,665

 

Financing activities

 

 

617